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ASSESSMENT OF THE ANTI-INFLAMMATORY EFFECTS OF ENONE-
CONTAINING COMPOUNDS IN THE CELL-BASED NF-κB REPORTER SYSTEM. 
  
ASSESSMENT OF THE TISSUE- AND CELL-SPECIFIC EXPRESSION AND 
SIGNALING OF RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS  
 
Julia V. Gefter, M.D. 
The NF-κB transcription factor family plays a central role in many aspects of the immune 
response, and activation of this family of transcription factors has been shown to trigger many 
disease processes.  Thus, the ability to modulate NF-κB activity may be an attractive way to treat 
these diseases.  We used an in vitro cell-based assay to test potential NF-κB inhibitors by 
measuring their effect on IL-1β-induced expression of the NF-κB dependent intracellular 
adhesion molecule-1 (ICAM-1, CD54). We tested ethyl pyruvate, a novel anti-inflammatory 
drug candidate, and the ability of related compounds to block activation of NF-κB activity by 
measuring the expression of CD54 on U373 cells exposed to IL-1β.  4-hydroxyphenylpyruvic 
acid was the best inhibitor of CD54 upregulation. These studies show the ease of using an 
endogenous reporter gene (i.e., CD54) and FACS analysis to rapidly characterize the relative 
efficacy of pharmacologic inhibitors.  A second completely unrelated topic of the dissertation 
dealt with the receptor for advanced glycation end-products (RAGE).  RAGE is thought to be 
important in a variety of pathological conditions, including diabetes, sepsis, atherosclerosis, renal 
diseases, hypertension and Alzheimer’s disease. However, RAGE proximal signaling events are 
still unclear. We were able to establish that original RAGE, sequenced from bovine lung, is only 
present in the lung. This observation was based on antibody specificity, Northern blotting and N-
glycosylation analysis. One of the antibodies that we used (H-300, Santa Cruz, CA) was very 
selective for lung RAGE and not cross-react with other RAGE isoforms. Only lung RAGE had a 
transcript size of 1.4 kb as determined by Northern blot and only lung RAGE was N-
glycosylated. Non-lung tissues and cell lines appeared to express their own unique RAGE 
isoforms. In addition, we established that previously described endogenous soluble RAGE 
(esRAGE) does not contain any of the canonical RAGE epitopes, but includes sequence encoded 
in intron 9. Signaling studies with pro-inflammatory stimuli in mouse lung slices of wild-type 
and knockout mice revealed the importance of RAGE in LPS and IL-1β-induced inflammatory 
response, but not when reported RAGE ligands, including AGEs, HMGB1 and S100B, were 
applied. 
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1.0  INTRODUCTION 
Inflammation is involved in a variety of processes in health and disease. In general, a 
controlled inflammatory response could be beneficial, but a chronic and/or dysregulated response 
may be detrimental. An unbalanced response may lead to septic shock, cancer, allergies, and 
many other detrimental effects (1-3). 
In order to manage unbalanced inflammation, more diverse pharmacological approaches 
offering better targeting and/or specificity are needed. This dissertation consists of several 
interrelated projects relevant to the mechanisms and treatments of inflammation. Our first focus 
was on the use of the enone-containing compounds (unsaturated compounds consisting of a 
conjugated system of an alkene and a ketone) to modulate the inflammatory response. These 
studies were based on the hypothesis that the enone can modify cysteine residues in NF-κB, a 
central inflammation-associated transcription factor. This modification interferes with DNA 
binding and expression of endogenous NF-κB-dependent genes. We made use of a clonal 
astrocytoma cell line to compare efficacy of different enone containing compounds to decrease 
activation of the endogenous CD54 gene, also known as ICAM-1 (inter-cellular adhesion 
molecule 1). Our second focus was studying the expression of tissue- and cell line-specific 
isoforms of the receptor for advanced glycation end-products (RAGE), a protein that is thought 
to play a role in inflammation. Finally, our third focus was examining several RAGE ligands in 
signaling experiments in cell lines and in mouse lung slices.  
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 1.1 SCREENING OF ANTI-INFLAMMATORY PROPERTIES OF ENONE 
CONTAINING COMPOUNDS  
1.1.1 The NF-κB pathway in inflammation 
The NF-κB transcription factor family plays a central role in many aspects of the immune 
response, and activation of this family of transcription factors has been shown to underlie many 
disease processes including AIDS, atherosclerosis, asthma, arthritis, cancer, diabetes, 
inflammatory bowel disease, muscular dystrophy, stroke, and viral infections (4).  Thus, the 
ability to modulate NF-κB activity is attractive in terms of possible therapeutic approaches. 
Originally identified as a transcription factor involved in the activation of the κ light chain genes 
in B lymphocytes (5), NF-κB is now known to be controlled by over 150 stimuli and to regulate 
the expression of more than 150 genes (6). Members of the Rel/NF-κB transcription factor 
family include p50, p65 (RelA), c-Rel, p52, and RelB, which is represented by multiple splice 
variants (7). In resting cells, homo- or heterodimeric forms of NF-κB exist in the cytoplasm in an 
inactive form due to binding by an inhibitory protein called IκB (8). Following exposure of cells 
to an appropriate pro-inflammatory stimulus (e.g., IL-1β), IκB is phosphorylated and targeted for 
ubiquitination and subsequent proteasomal degradation (9, 10) (Fig. 1). Phosphorylation, release, 
and degradation of IκB permits translocation of NF-κB into the nucleus where it can bind to cis-
acting elements in the promoter regions of various NF-κB-responsive genes. Different dimer 
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combinations could serve as transcriptional repressors or activators and have different affinity 
and specificity for NF-κB binding sites. p50/p65 heterodimer was studied the most. 
 
 
 
Figure 1.  Schematic representation of NF-κB activation.  
In this figure, the NF-κB heterodimer between RelA and p50 is used as an example. While in an inactive state, 
NF-κB is located in the cytosol complexed with the inhibitory protein IκBα.  A variety of extracellular signals 
can activate the enzyme IκB kinase (IKK). IKK, in turn, phosphorylates the IκBα protein, which results in 
ubiquitination of IκBα and degradation of IκBα by the proteosome. Released NF-κB is then translocated into 
the nucleus where it binds to specific sequences of DNA called response elements (RE). The DNA/NF-κB 
complex then recruits other proteins, such as co-activators and RNA polymerase, which transcribe 
downstream DNA into mRNA, which, in turn, is translated into protein, resulting in a change of cell function 
(11). 
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1.1.2 The enone moiety may react with the thiol groups of NF-κB 
Ethyl pyruvate was first studied as a derivative of sodium pyruvate which has been shown to 
preserve organ function in vivo (12-14). However, sodium pyruvate is unstable in the aqueous 
solutions forming parapyruvate and pyruvate hydrate (15). Sims et al. used the ethyl ester of 
pyruvic acid, ethyl pyruvate, because it was expected to be more stable in aqueous solution 
compared to pyruvic acid. Interestingly, ethyl pyruvate was far more protective in a rat intestinal 
ischemia model when compared to sodium pyruvate (16). 
Ethyl pyruvate exhibits anti-inflammatory activity in many in vitro and in vivo assays. 
Pyruvic acid and sodium pyruvate, which are structurally similar to ethyl pyruvate, have been 
reported to scavenge reactive oxygen species (ROS). But Sappington et al. showed that even 
short transient exposure to ethyl pyruvate was enough to provide protection against cytomix-
induced hyperpermeability in immunostimulated Caco-2 human enterocyte-like cells. Ethyl 
pyruvate was washed off the cells extensively several hours before pro-inflammatory stimulation 
This would prevent ROS scavenging activity suggesting that other mechanisms exist (17). 
However, it is still possible that the cells rapidly internalize ethyl pyruvate and it would not be 
removed by cell washing. Further research is needed to eliminate this possibility.  
ROS are considered to be a major cause of intracellular damage associated with 
inflammatory conditions (18). Glutathione (GST) is an essential tri-peptide with the side chain 
sulfhydryl residue that protects cells against free radical damage; the GST redox status of the 
cells  is crucial for various biochemical events, including inflammation (19). GST levels have 
been reported to diminish in response to TNFα and glucocorticoids (dexamethasone) (20). So it 
is reasonable to suggest that oxidizing drugs like ethyl pyruvate and derivatives would be 
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inactive in the reducing healthy cell environment with plenty of GST around. But in the 
inflammation when GST is depleted they would be able to interact with NF-κB. Numerous 
studies have shown that NF-κB DNA-binding activity is inhibited by oxidizing agents or 
electrophilic compounds that can react with thiols (21), suggesting that one or more reduced 
cysteine residues in NF-κB are critical for its activation. Compounds containing the electrophilic 
“enone” moiety may cause modification of the thiol groups in proteins (22, 23) via a Michael-
type addition reaction. This is shown for ethacrynic acid in the following figure:                         
ethacrynic acid protein
 
 
Figure 2. Hypothetical reaction of ethacrynic acid with sulfhydryl groups to form a thiol adduct  (23). 
 
This notion is supported by data in a brief report published several years ago by Brennan and 
colleagues where they show that thiol modifying compounds inhibited NF-κB activation in 
several cell lines (24). Another group of compound, the sesquiterpene lactones, is known to act 
this way. They inhibit NF-κB activation by alkylating a critical cysteine residue (Cys38) in the 
p65 subunit of NF-κB (25-27). Data from our laboratory suggest that ethyl pyruvate can also 
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inhibit p65 DNA binding by modifying Cys38 (28), and ethacrynic acid can modify Cys38 in p65 
and another cysteine-containing residue in p50 (29). Han el al. compared DNA binding of wild- 
type and mutant p65 (Cys38 → Ser and Cys38 →Ala). Ethyl pyruvate inhibited binding by the 
wild-type and alanine-substituted p65 mutant; however, it failed to inhibit binding of Cys38 → 
Ser mutant. Ethyl pyruvate could also inhibit basal p65 DNA binding in unstimulated RAW 
264.7 cells which is consistent with interfering with binding itself and not with activation steps 
of this transcription factor. In addition, ethyl pyruvate did not affect IκBα and IκBβ degradation 
(28).  Thus, it is reasonable to hypothesize that compounds containing an electrophilic enone 
moiety may modify critical thiol residues in NF-κB.   
Therefore, we compared several compounds that contain or lack an enone moiety for 
their ability to inhibit NF-κB-dependent activation. We chose cell surface expression of the 
inflammation marker CD54 in U373 astrocytoma cell line as was described before (30). We 
selected and cloned cells that had minimal basal expression of the marker and maximum 
expression upon pro-inflammatory stimulation (IL-1β). It is important to realize that actual 
modification of NF-κB transcription factors by the drugs themselves has not been formally 
shown.  
1.2 RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS (RAGE) 
RAGE is involved in promoting recruitment and activation of inflammatory cells (31, 32), cell 
adhesion and spreading (33), stimulating cell migration (34, 35), and upregulation of pro-
inflammatory cytokine production (36). RAGE was first identified as an advanced glycation end-
products (AGE) - binding protein present in bovine lung protein extracts (37) which was 
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subsequently shown to bind a variety of ligands including amyloid-β peptide and β sheet fibrils 
(38), members of a small Ca2+-binding protein family called S100/calgranulins (39), and 
HMGB1, a DNA-binding protein (also called amphoterin) (40). The RAGE extracellular domain 
sequence encodes one “V “-type Ig domain followed by two “C”-type Ig domains (41).  
RAGE ligands were shown to compete for binding to the V-type Ig domain of RAGE using 
radioligand-binding assays (39, 42). RAGE has also been shown to be a counter-receptor for the 
β2-integrin Mac-1, (CD11b/CD18) mediating leukocyte recruitment and adhesion to sites of 
inflammation (32). Mac-1 interaction is enhanced by S100B (32) and by HMGB1 (31). These 
findings emphasize the importance of RAGE during acute inflammatory response involving 
neutrophil recruitment and activation.  
Recently, RAGE was added to the group of pattern-recognition receptors (PRRs), which 
are  expressed by cells to identify pathogen-associated molecular patterns (PAMPs), based on its 
ability to interact with several classes of molecules, rather than individual ligands, and to amplify 
the inflammatory response (43, 44).   
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 Figure 3. Schematic representation of RAGE.  
Domains of RAGE are shown with corresponding amino acid numbers (45).  
 
Given the large number of apparent RAGE-ligands, it is not surprising that RAGE has been 
implicated in the pathogenesis of a variety of human diseases including Alzheimer’s disease, 
diabetes mellitus, severe sepsis, hemorrhagic shock, rheumatoid arthritis, cancer and 
inflammatory bowel disease (reviewed in ref 46, 47). Schmidt et al. developed two-hit model of 
vascular perturbation mediated by RAGE. First hit includes increased expression of RAGE and 
RAGE ligands, therefore resulting in a constant state of activation; a superimposed stimulus such 
as an inflammatory response, tissue damage or ischemia leads to the constant state of vascular 
dysfunction and tissue damage rather than restoring of homeostasis (41). 
RAGE has also been shown to play an important role in the natural aging process. 
Inflammation, through generation of reactive oxygen species (ROS), oxidative stress and 
inflammatory cytokines, increases generation of AGEs and decreased anti-AGE defense leading 
to accumulation of AGEs. Adhesion molecules attract inflammatory cells; NFκB activation itself 
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up-regulates RAGE expression in turn amplifying inflammation and making it chronic. 
Eventually tissue damage becomes irreversible (47). 
1.2.1 RAGE tissue-specific expression 
RAGE was partially sequenced after it was first purified from bovine lung protein 
extracts as lung was an excellent source of endothelial cell AGE-binding activity (48); 
consequently RAGE mRNA was demonstrated to be highly expressed in lungs (49). 
Interestingly, later studies revealed that RAGE in the lung was localized to the epithelial rather 
than endothelial cells. Although RAGE mRNA levels were reported to be the highest in type II 
alveolar epithelial cells in rat by in situ hybridization (50), most researchers, including us, view 
lung RAGE as an exclusive type I alveolocyte marker which is not present in type II cells or 
endothelial cells (51-54). Shirasawa et al. and Fehrenbach et al. utilized immunoelectron 
microscopy and showed lung RAGE expression exclusively in type 1 alveolar cells. Dahlin et al. 
identified the differentially expressed genes in freshly isolated rat type I and type II alveolocytes. 
This was done by creation of an mRNA subtraction library and confirmed the results by 
Northern blotting; RAGE was found to be expressed in type I cells (53). 
The RAGE promoter sequence contains two apparently functional NF-κB binding sites 
(55). Full-length RAGE is considered to be a pro-inflammatory factor as it is able to trigger NF-
κB signaling. This results in the up regulation of full-length RAGE as well as other factors in 
response to ligand binding to RAGE receptor and to general inflammatory stimuli (LPS, IL1-β 
etc.).  According to our unpublished observations, cultured cells transfected with canonical 
RAGE up regulate their RAGE protein expression in response to IL-1β and LPS. sRAGE is 
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believed to be a decoy receptor only able to bind the ligands and therefore is an anti-
inflammatory factor.  
RAGE expression is tightly regulated at different levels depending on the tissue and 
condition (healthy or diseased) of the cell. It is highly expressed in embryo and is downregulated 
in adult tissues. The known exceptions are lung, muscle and skin (33, 56, 57). RAGE is 
abundantly expressed in lungs of humans, dogs (58, 59),  rats (51) and mice (60, 61). Reportedly, 
RAGE expression could be induced in generalized pathological conditions (inflammation) (57, 
62)  and lung diseases such as idiopathic pulmonary fibrosis (60, 63).  
Studying RAGE expression is particularly difficult because it has overlapping sequence 
with the gene of pre-B-cell leukemia homeobox 2 (PBX2), a transcription factor implicated in 
the development of pre-B cell leukemia, on the chromosome 6 (-1204-507). PBX2 in turn has a 
pseudogene copy on chromosome 3 (64). The shared sequence between two genes has to be 
taken into account when studying gene expression/polymorphism using RT-PCR analysis 
because of the possibility of false positive PCR analysis. PCR primers should be designed to 
avoid the shared sequences between RAGE and PBX2.  
1.2.2 RAGE isoforms 
Multiple RAGE isoforms are reported to arise through alternative splicing and/or proteolysis.  
The first RAGE isoform identified, often referred to as “full-length” RAGE, is a type-Ia 
transmembrane protein with a cleavable signal peptide, an NH2-terminal oriented towards the 
extracellular space, a single transmembrane domain and an intracellular COOH-terminal.  The 
NH2-terminal of the mature peptide contains one variable-type and two distally located constant-
type Ig domains that are required for ligand binding.  The COOH-terminal consists of 43 amino 
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acids and does not appear to contain significant homology to known functional protein domains.  
The cytosolic tail is thought to be essential for RAGE intracellular signal transduction following 
receptor engagement (65, 66).  
Mouse lung was reported to express two major RAGE protein isoforms including the 
full-length transmembrane RAGE isoform and a soluble RAGE (sRAGE) (61). In addition, 
Harashima et al. identified endogenous soluble RAGE carboxyl-truncated isoform (esRAGE) in 
the mouse lung and other organs (brain, kidney and small intestine) (67). Human esRAGE and 
an amino-truncated transmembrane isoforms have been previously described by Yonekura et al. 
(68) in cultured human endothelial cells and pericytes together with a full-length transmembrane 
RAGE isoform. Interestingly, sRAGE is thought to be produced by proteolytic cleavage and 
esRAGE appeared to arise through alternative splicing (61, 67). Proteolysis is thought to require 
matrix metallo-proteinase-9 (61) and/or ADAM metalloproteinases, in particular ADAM 10 (69, 
70). Ding and Keller (71, 72) reported the existence of at least six RAGE isoforms detected in 
human brain using RT-PCR: a full-length isoform, an isoform lacking the carboxyl-terminus, 
two soluble protein isoforms, and two N-truncated isoforms.  Schlueter et al. (73) used RT-PCR 
to demonstrate that three sRAGE isoforms were present in human lung, lymph node, breast 
carcinoma and myometrium.  Park et al. (74) described another soluble RAGE isoform, Δ8-
RAGE, which was detected in human astrocytes and peripheral blood mononuclear cells 
(PBMCs). It lacks exon 8 of the original transcript and contains an early stop codon in exon 10 
resulting from frameshift. Malherbe et al. cloned and analyzed yet another soluble RAGE, 
hRAGEsec, which lacks 19 amino acids corresponding to the membrane-spanning domain. It 
was confirmed to be expressed in brain and appears to be a decoy receptor for β-amyloid 
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precursor protein (75). All soluble RAGE isoforms are believed to act as decoy receptors 
diminishing pro-inflammatory effects of the full-length receptor. 
Hudson et al. (45) recently published a summary of different RAGE isoforms as detected by 
RT-PCR (presented in table 1). The work was based on the analysis of RAGE mRNA transcripts 
in human lung and in human primary aortic smooth muscle cells (AoSMCs). In addition to the 
‘classical’ full-length transmembrane RAGE mRNA they identified a range of RAGE RNA 
splice variants including 3 previously described isoforms and 10 novel isoforms. They were 
unable to confirm 6 previously reported isoforms.  Tissue and cell lines expressed different 
relative amounts of each RAGE transcript. Half of the detected mRNA transcripts possessed 
premature termination codons and were targeted for degradation. Although, polyadenylation sites 
were identified in the untranslated region of these amplified cDNA, polyadenylation of the 
RNAs themselves has not been proven. So the presence of mature mRNA for the splice variants 
discovered in this study has never been confirmed and it is reasonable to suggest that some or all 
mRNA transcripts were not translated into proteins. In the next step authors generated isoform-
specific antibodies for the newly discovered RAGE proteins. However, instead of using the cell 
lines that were initially utilized for mRNA analysis they transfected HEK293 cell line with the 
cDNAs and used antibodies to probe for the transfected and not endogenous RAGE. This  
 
Table 1. Splice map of different RAGE variants detected in human lung and human primary aortic smooth 
muscle cells (AoSMC) cDNA. 
Previously identified variants detected here are shown in blue, novel variants in red, and other variants not 
detected in this study in green (45). 
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approach raised the question of very existence of the endogenous RAGE isoforms which was just 
discovered in the first part of the study. 
The authors made a huge effort in cataloguing RAGE isoforms but the following questions 
still remain: 1. What different RAGE proteins are expressed in different tissues/cell lines? 2. 
What factors contribute to RAGE processing including RNA splicing and proteolysis? 3. What is 
the difference between the various RAGE isoforms in terms of ligand binding and signaling? 4. 
What is the significance of particular RAGE isoforms in health and disease? 5. What is the 
proportion of RAGE isoforms at the site of inflammation? 
1.2.3 RAGE signaling in cell physiology 
RAGE was discovered based on its high affinity for AGEs and is thought to be more of an 
accidental receptor for (76) since AGEs have at least eight  other receptors and RAGE has 
multiple ligands. It shares structural homology with other Ig-like receptors (such as ICAM-1) 
and could very well be functionally similar acting as an adhesion molecule.  
Although RAGE was first discovered as a protein that binds AGEs (48), and studies have 
convincingly shown that AGEs bind to RAGE in a dose-dependent manner, there have been 
reports showing either a lack of signaling induced by AGEs (77-80) or negative (anti-
inflammatory) responses (81, 82). Several reports question the ability of RAGE to effect 
transmembrane signaling events in response to known RAGE ligands including AGEs although 
confirming binding affinity of AGEs to RAGE (77, 78).  There are many reports stating that 
AGEs signal through RAGE but in at least some of them the strong possibility exists that the 
AGEs used in some experiments have been contaminated with proinflammatory bacterial 
products; many of the studies did not use proper controls.  
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Another issue arises from studies of diabetes. Increased serum glucose leads to glycation 
of extracellular proteins. Those become irreversibly oxidized and are thought to bind to and 
activate RAGE. Most RAGE-expressing organs (lung, muscle and skin) do not seem to be 
affected by diabetes, the pathology related to AGEs.  If AGEs were actually capable of triggering 
a pro-inflammatory response through RAGE, those organs would be expected to have more 
diabetes-related problems (83).  
Strong arguments have been made against RAGE involvement with dietary AGEs which 
are generated in the Maillard reaction the same way AGEs are made in biological systems. The 
Maillard reaction involves reducing sugars that modify proteins thus changing their properties. 
The relationship between dietary AGEs and AGEs in biological systems is still unclear (84). 
Dietary AGEs would have to be digested in the gastrointestinal tract and be absorbed into the 
blood stream, at which point the AGEs might not be able to activate RAGE. Maillard reaction 
products of low molecular weight are unlikely to interact with RAGE - high molecular weight 
proteins are unlikely to enter the blood stream. They would be toxic through RAGE-independent 
mechanisms (84).  In regards to endogenous proteins, only a small fraction of them are glycated 
and they contain too few modifications per protein, which could be insufficient for RAGE 
binding. In addition, the AGEs would have to compete with other RAGE ligands, and the 
concentrations of those (S100 proteins and HMGB1) would prevail under inflammatory 
conditions as they are released locally from activated cells (83).  
The exact mechanisms involved in RAGE-mediated cell signaling remain to be 
elucidated. RAGE signaling is thought to follow binding of the ligand  to the receptor and to 
employ the mitogen activated protein (MAP) kinase ERK 1/2 (p44/p42), stress-activated protein 
(SAP) kinases p38 and JNK, and the downstream NF-κB signaling cascades (66, 85-87). There is 
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a single report suggesting that the RAGE intracellular domain interacts with ERK 1/2 directly 
(88) when using recombinant full-length RAGE expressed in the cell lines that do not normally 
express the full-length RAGE. This result is questionable since it has not been repeated since the 
original publication. 
Recently, there have been studies indicating that RAGE-binding ligands may in fact 
utilize non-RAGE receptors, at least in part, to induce signal transduction.  In turn, every RAGE 
ligand has been shown to bind a unique non-RAGE receptor(s) and/or binding partner(s). AGEs 
bind SR-A (class A scavenger receptor types I and II) and SRB, CD36, SR-BI (scavenger 
receptor class B type-I), galectin-3, LOX-1 (lectin-like Ox-LDL receptor-1), HA-SR (hyaluronan 
scavenger receptor, and RAGE. Additionally, it binds to an unidentified non-RAGE receptor in 
A549 cells (89, 90). By means of a RAGE-independent mechanism, S100B exhibits myogenic 
differentiation  and apoptotic effects on cells (91, 92).  The role of RAGE in amyloid-β peptide 
toxicity has  been questioned (93); recent studies suggest that HMGB1 binds to and signals 
through Toll-like receptors 2 and 4 (94, 95) to the exclusion of RAGE and TLR9 (96).  It appears 
that not only RAGE has multiple potential ligands, but each of those ligands has targets in 
addition to RAGE. 
Despite tremendous efforts in the field, mechanisms involved in diversity of RAGE 
signaling in response to individual ligands still remains unclear. There is also a question of the 
contribution of different RAGE isoforms to the signaling events resulting in observed 
pathologies. On one hand, there is a number of RAGE isoforms expressed in different tissues, 
and on the other hand, there are many putative RAGE downstream signaling cascades. RAGE 
protein is upregulated in inflammation but the proportion of each RAGE isoform (full-length vs. 
soluble) is unknown. As stated before, the relative contribution to RAGE signal transduction by 
 16 
the various isoforms remains to be determined. There are no studies addressing RAGE signaling 
specific to inflammation, tumorigenesis, diabetes, etc.  
As for the inhibiting RAGE signaling in order to diminish inflammation, there are some 
concerns that in fact NF-κB activation is necessary to mount an effective immune response to 
invading pathogens. RAGE knockout mice have diminished immune response which could harm 
immune defense to some extent (97). Therefore the use of anti-RAGE directed therapies should 
be approached with caution.  
1.2.4 Role of RAGE in inflammatory cell recruitment 
In addition to the ‘classical’ RAGE-binding partners (AGEs, β-sheet fibrils, S100B and 
HMGB1), RAGE, along with ICAM-1, was shown to be a counter receptor for β2-integrins 
Mac-1 and, to a lesser extent, for p150, 95 (32). Direct interaction between RAGE and Mac-1 
was shown in a purified system using transfected cells and in vivo (in mice) (32). sRAGE, anti-
Mac-1 antibody and anti-ICAM-1 antibody were used as negative controls. Interestingly, 
classical RAGE ligands, namely S100B and HMGB1, augmented RAGE binding to Mac-1 
promoting leukocyte recruitment (31, 32, 44). While RAGE expression in healthy organs, except 
for lung, is thought to be very low, it is reported to become upregulated in inflammation and at 
places where RAGE ligands accumulate (41, 55, 98). It is particularly important in diabetic 
vasculature in the presence of AGEs (99). AGEs are thought to mediate the inflammatory 
response and increase vascular permeability that contributes to diabetic vasculopathy, while 
RAGE modulates leukocyte adhesion, recruitment, and extravasation. sRAGE could be a 
therapeutic drug of choice in this model (32, 44).  
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1.2.5 RAGE studies in animals  
In animal studies, RAGE knockout mice were found to be less susceptible to diabetic 
nephropathy, atherosclerosis, and inflammation (reviewed in (100)). Since sRAGE is generally 
viewed as a decoy molecule, it was used to treat different pathological conditions. 
Administration of sRAGE was found to be beneficial in tumor treatment (40), diabetic 
atherosclerosis (101), and diabetic wound healing (102). It also protected myocardium from 
ischemic damage (103) and preserved intestinal barrier after hemorrhagic shock (104). 
Surprisingly, sRAGE had an advantageous effect in the cecal ligation and puncture model of 
polymicrobial peritonitis in mice when administered to RAGE knockout mice compared with 
wild-type mice (105). This may be explained by the ability of sRAGE to bind potential RAGE 
ligands in the absence of the RAGE receptor which is helpful because RAGE ligands have pro-
inflammatory effects thus modulating inflammatory process.  
RAGE is highly expressed in the lung therefore it was predicted to play a role in the lung 
disease pathogenesis. In, in bleomycin mouse model of idiopathic pulmonary fibrosis authors 
observed loss of membrane and sRAGE, which was predicted to have beneficial effects; sRAGE 
was predicted to have beneficial effects (63). In an asbestos model, both RAGE isoforms were 
also downregulated, but in addition, RAGE knockout animals spontaneously developed 
pulmonary fibrosis. The disease is enhanced in the RAGE knockout mice in an asbestos-induced 
model of fibrosis compared with wild-type littermates (60). Those studies suggest protective role 
of RAGE in the pulmonary fibrosis.  It is not clear that RAGE is detrimental in pathological 
conditions. It could also be associated with the protective immune response.  
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1.2.6 The role of sRAGE in disease 
Uchida et al analyzed BAL fluids and found that soluble RAGE (sRAGE) could be a selective 
marker of type I cells damage in acute lung injury. 
Soluble RAGE isoforms (including sRAGE, esRAGE, Δ8-RAGE and others) are thought to act 
as decoy molecules that bind RAGE ligands without triggering signal transduction. Mouse 
sRAGE has been shown to be a result of proteolysis (61), and human sRAGE is considered to be 
a product of alternative splicing. Endogenous soluble RAGE (esRAGE) was discovered by 
reverse transcribing mRNA library from human microvascular endothelial cells and pericytes, 
amplifying and sequencing resulting cDNA clones (106). esRAGE is generated by alternative 
splicing and contains 5’ part of intron 9 and not exon 10 which encodes transmembrane domain. 
Multiple reports have been published concerning the plasma level of esRAGE isoforms in 
diabetes (107), atherosclerosis (108), renal diseases (109), hypertension (110) and Alzheimer’s 
disease (111).  
It appears that circulating levels of soluble RAGE isoforms, in general, were associated 
with a lower risk of complications, better prognosis and, in a few studies, lower mortality. 
Yamagishi et al.(112) reported that circulating esRAGE levels positively correlated with the 
serum level of AGEs in non-diabetic subjects; Tan et al. made the same observation in subjects 
with type 2 diabetes (113). In some cases, however, sRAGE indicated a poor prognosis. For 
instance, in septic patients, esRAGE levels were elevated in comparison with healthy controls, 
and non-survivors had higher levels of sRAGE compared to survivors (114). In addition, sRAGE 
levels in type 2 diabetic patients were shown to positively correlate with important markers of 
inflammation such as tumor necrosis factor (TNF) -α and monocyte chemoattractant protein 1 
(MCP-1), making it of interest as a possible biomarker of vascular injury (115). 
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It is unclear if those levels could be viewed as prognostic markers of the disease or rather 
as a defense mechanism against the pathological condition (116). In other words, sRAGE could 
indicate a reaction of the organism to the pathological condition and/or a protective mechanism 
to minimize this condition. Further studies are necessary to understand the place of sRAGE in 
the development of the disease, including longitudinal ones, where RAGE is measured over a 
period of time along with other parameters/markers.  
 sRAGE has been considered as a candidate for a biomarker for acute lung injury, 
especially for patients on with mechanical ventilation. It is unclear however whether sRAGE 
blood levels rise as a result of injured lungs or as a part of an anti-inflammatory response (117).   
1.3 SUMMARY AND CONCLUSIONS 
Inflammation plays an important role in the interactions of the organism with the environment. 
The NF-κB family of transcription factors is a major part of the inflammatory response. In the 
first part of this dissertation we screened enone-containing compounds for their abilities to 
modulate the inflammatory response. This was based on the hypothesis that the compounds 
modify NF-κB therefore preventing it from binding to DNA. In the second part we evaluated 
RAGE protein isoforms expressed in cell lines and tissues. Scientific publications report multiple 
RAGE isoforms; most of them however were discovered by RT-PCR. Very little is known about 
RAGE protein isoforms, sequences, locations and functions. We used molecular biology tools 
available to us to address those questions which are undoubtedly important in RAGE-related 
pathologies and treatments. We also attempted to summarize cellular responses to RAGE ligands 
(AGEs, HMGB1 and S100B).  
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2.0  CHAPTER TWO – USING IN VITRO CELL-BASED SYSTEMS TO ASSAY ENONE-
CONTAINING ANTI-INFLAMMATORY DRUGS 
2.1 ABSTRACT 
  We showed that exposing the human U373 astrocytoma cell line to IL-1β increased the surface 
expression of intracellular adhesion molecule-1 (ICAM-1; CD54).  However, when the bulk 
population of U373 cells (stock obtained from the American Type Culture Collection) was 
exposed to IL-1β, only 50-60% of the cells appeared to express CD54. We used fluorescence 
activated cell sorting (FACS) to enrich for CD54-expressing cells following exposure to IL-1β. 
Six clonal cell lines were obtained and found to express CD54 in a higher percentage of cells 
(70-98%) compared to the bulk population.  However, some of these clones were also found to 
express slightly elevated baseline levels of CD54 compared to the non-sorted population. We 
used the protease inhibitor N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) to block 
proteasome activity and this almost completely blocked upregulation of CD54 expression in 
these cells, which is consistent with the dependence of CD54 expression on NF-κB activation. 
The sorted cell line was in screening substances for anti-inflammatory and, more specifically, 
NF-κB blocking activity. We utilized this endogenous NF-κB reporter system to study the 
relative efficacy of several compounds that have similar chemical properties to ethyl pyruvate, a 
promising new candidate compound for the treatment of a variety of systemic and localized 
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inflammatory diseases. We discovered that the endogenous metabolite para-hydroxyphenyl 
pyruvate was more potent then ethyl pyruvate. These studies show the value of using U373 cells 
as a reporter cell line for studying the relative pharmacology of anti-inflammatory drugs that 
work by blocking the activation of NF-κB. Utilizing an endogenous reporter gene (i.e., CD54) as 
a read out may have certain advantages over other engineered NF-κB-dependent reporter 
systems. 
2.2  RESULTS 
2.2.1 Establishing a cell-based U373 reporter cell line to screen compounds for NF-
κB inhibitory activity  
The U373 human glioblastoma astrocytoma cell line was used for these experiments because it 
has low background expression levels of CD54 which increased with IL-1β stimulation. 
Approximately 60% of all cells became CD54 positive upon stimulation with the pro-
inflammatory factor. We wanted to enrich the parental population for IL-1β-responsive cells so 
we stimulated the bulk cell population with IL-1β and stained the cells for CD54 expression, and 
sorted them with a fluorescence activated cell sorter (FACS) selecting for the CD54 expressing 
cells. The sorted cells were plated on a T25 tissue culture flask and allowed to expand. They 
were cloned using cloning cylinders and assayed, along with the bulk population, for both 
background and stimulated expression of CD54. The percent stimulation for the bulk population 
and for the individual clones was determined (Fig. 4, 5). For the experiments, we used the bulk 
cell population as well as individual clones that became more than 90% CD54 positive following 
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exposure to IL-1β. We generated a calibration curve of increasing IL-1β concentrations vs. 
increasing expression of CD54 (Fig. 6). As a control for the system, we used the protease 
inhibitor N-tosyl-L-phenylalanine chloromethyl ketone, (TPCK), which blocks proteasome 
activity and thus almost completely abolished upregulation of CD54  
PBS
IL-1β
parental sorted
 
Figure 4. FACS enriched U373 cell population stimulated with IL-1β.   
96.3% cells express CD54 vs. 59.8% in the parental population.  Histograms show results of stimulating 
parental and sorted U373 reporter cell lines. 
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Figure 5. FACS enriched clonal U373 NF-κB reporter cell lines.  
Histograms show results of stimulating two clonal U373 reporter cell lines stimulated with 10 ng/ml IL-1β. 
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 expression in these cells (data not shown), confirming the dependence of CD54 expression on 
NF-κB activation. TPCK is a serine protease inhibitor that has been shown to inhibit NF-κB 
activation by blocking I-κB phosphorylation and subsequent degradation via proteasome (118). 
Our in vitro system was ready to screen NF-κB inhibitors. The definite advantage of this in vitro 
cell system is the endogenous origin of the readout protein (CD54). 
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Figure 6. Graded IL-1β-induced CD54 cell surface expression on the bulk sorted population of U373 cells as 
measured by FACS analysis.  
Cells were stimulated with the indicated concentrations of IL-1β and stained as described in Methods. After 
evaluating percentage stimulation of the sorted cells we performed calibration curve of the graded IL-1β 
concentrations vs. CD54 expression. We were able to show that mean channel fluorescence (MCF) increased 
from 2.4 with no stimulation to 6.8 with upon stimulation with 10 ng/ml IL-1β.  The results are representative 
of 2 different experiments. 
2.2.2 Using the clonal U373 human astrocytoma cell line in the screening of the 
enone-containing compounds 
To screen the enone-containing compounds, we grew sorted U373 cells in the 6-well dishes, 
treated them with the indicated compound and stimulated them with IL-1 β the next day. CD54 
surface expression was assayed 18 h later. In this experiment, the groups consisted of: unstained 
cells, stained unstimulated cells, stained stimulated cells and stained stimulated cells treated with 
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the compound of interest. Percent inhibition for each compound was determined by comparing the 
mean channel fluorescence (MCF) of cells stimulated with IL-1β with the MCF of cells pretreated 
with the drug of interest prior to stimulation with IL-1β. We compared the ability of ethyl pyruvate 
(ET), sodium pyruvate (SP), para-hydroxyphenyl pyruvate (pHPP) and benzoyl formate (BF) to 
inhibit CD54 expression. The results are presented in Fig. 7.  
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Figure 7. pHPP exhibits the best inhibitory properties on CD54 cell surface expression after IL-1β 
stimulation in bulk sorted population of U373 cells.   
CD54 was measured by FACS analysis. Percent inhibition is determined from mean channel fluorescence as 
described in Methods. Results are presented as means±SD (N=4 per conditions). 
All compounds were tested at 4 concentrations (1, 10, 20 and 30 mM). EP and pHPP 
exhibited comparable abilities to inhibit CD54 expression. However, pHPP worked better than 
ethyl pyruvate at the 10 mM concentration. SP had no significant effect on CD54 expression and 
BF exhibited a minimal effect that did not increase with increasing concentration.  In this 
experiment, we demonstrated that the U373 human astrocytoma cell line can be used as a test 
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system for potential anti-inflammatory drugs and that it is responding to anti-inflammatory agents 
in a dose-dependent manner. It allowed us to compare enone-containing compounds for their anti-
inflammatory activity using endogenously expressed protein (CD54) as readout. 
2.2.3 Using RAW 264.7 murine macrophage-like cell line for further testing the 
enone-containing compounds 
Since NF-κB is thought to play a role in inflammation, we further tested our compounds using the 
mouse macrophage-like RAW 264.7 cell line. RAW cells are very sensitive to bacterial 
lipopolysaccharide (LPS), producing a variety of cytokines and nitric oxide (NO·) in an NF-κB-
dependent manner. Tested drugs downregulated LPS-induced inflammatory responses (namely, 
IL-6 production, iNOS upregulation, and NO· production) following the same trend they 
demonstrated during primary screening in U373 cells (i.e. pHPP>EP>BF).  
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 Figure 8. Effect of graded concentrations of compounds of interest on NO· release by LPS-stimulated RAW 
264.7 cells.  
The cells were stimulated with LPS (10 ng/ml) for 18 h later supernatants were assayed for IL-6 and nitrite 
concentration using commercially available kits. Results are presented as means±SD (N=4 per conditions). 
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Figure 9. Real time quantitative RT PCR analysis showing iNOS expression after 18 hour incubation with 
LPS in the presence of the graded concentrations of the indicated drugs in RAW 264.7 cells.  
 The experiment was performed in duplicates. 
Ethyl pyruvate downregulated pro-inflammatory gene expression in various experimental 
models (119-122). In this experiment, we tested SP, BF, EP and pHPP at 5 graded concentrations. 
Ethyl pyruvate and pHPP inhibited NO· production and iNOS steady-state mRNA levels (Fig. 8, 
9). Under the tested conditions, pHPP appeared to be the most active compound. It showed the 
greatest inhibition, even in lower doses (1 mM), while the higher doses brought iNOS down to 
baseline levels.  Oxalproprionate and ethyl pyruvate also exhibited substantial iNOS-inhibiting 
activity at the higher doses. The ability of pHPP to inhibit inflammatory markers at lower doses 
could be beneficial for decreasing toxicity. 
2.2.4 pHPP inhibited LPS-induced IL-6 secretion in LPS-stimulated RAW 264.7 
cells 
 RAW cells were treated with 10 ng/ml LPS in the absence or presence of graded concentrations of 
the tested compounds. Cell culture supernatants were tested for IL-6 18 hours after LPS treatment. 
pHPP demonstrated the best IL-6 inhibiting activity at the 3 mM concentration. When used at 10 
mM, pHPP inhibited IL-6 below baseline. Oxalproprionate and ethyl pyruvate showed less 
inhibition when used at the higher concentrations (Fig. 10). 
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Figure 10. Effect of graded concentrations of compounds of interest on IL-6 by LPS-stimulated RAW 264.7 
cells.  
The cells were stimulated with LPS (10 ng/ml) for 18 h later supernatants were assayed for IL-6 and nitrite 
concentration using commercially available kits. Results are presented as means±SD (N=4 per conditions). 
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2.3 DISCUSSION 
First, we established a cell-based in vitro system for testing potential anti-inflammatory 
compounds containing an enone structure. U373 cells were enriched using a FACS and cloned to 
create a cell population with a low background CD54 expression and high expression upon 
stimulation with IL-1β. After the in vitro cell-based system was established, we performed tests 
which showed that the cells responded to IL-1β stimulation in a dose-dependent manner and that 
the proteasome inhibitor TPCK, which blocks Iκ-B degradation, completely abolished IL-1β 
stimulated CD54 upregulation. In this way, we confirmed that the system was indeed NF-κB 
dependent. Then, we were able to utilize the system for testing of ethyl pyruvate and related 
enone-containing anti-inflammatory compounds, which were shown to work in various in vivo 
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and in vitro systems (28, 123). Pyruvate is a part of intermediary metabolism and is considered to 
be an endogenous scavenger of reactive oxygen species (ROS) (124, 125). However, use of 
pyruvate in a biological system is limited by its poor stability in aqueous solutions (15). 
Eventually, ethyl pyruvate was proven to be more effective than pyruvate in in vivo and in vitro 
models (16, 126). Therefore we tested anti-inflammatory effects of ethyl pyruvate and related 
compounds. Our results showed that pHPP was the most potent drug along with ethyl pyruvate. 
Sodium pyruvate and benzoyl formate exhibited no NF-kB blocking activity. pHPP 
demonstrated anti-inflammatory effects in lower doses than ethyl pyruvate, which made it 
potentially a better candidate as a drug. This is also supported by the fact that pHPP is an 
endogenous catabolite of trypsin.  
After we tested enone-containing compounds in our newly developed system, we used 
another cell line - RAW 264.7 murine macrophage-like cells. RAW 264.7 are routinely used in 
the lab to test anti-inflammatory compounds; they produce various cytokines in response to LPS 
in a dose-dependent manner. We assayed iNOS expression using real-time RT PCR and we also 
collected supernatants to assay for NO· production and IL-6 secretion. In agreement with the 
U373 data, pHPP was the most effective drug in suppression of LPS-stimulated iNOS mRNA 
expression, followed ethyl pyruvate (Fig. 9). These data were closely followed by NO· 
production (Fig. 8) and IL-6 secretion (Fig. 10) where pHPP was again the most effective drug. 
Taken together, our results suggest that pHPP could be as effective, if not more, as ethyl 
pyruvate.  
As mentioned before, the mechanisms of the enone-containing anti-inflammatory 
compounds could be explain, at least in part, by modification of thiol residues on the p65 subunit 
of NF-κB decreasing its DNA-binding activity (28). Ethyl pyruvate has been shown to affect p65 
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basal binding in resting cells and it does not interfere with IκB degradation (28). These findings 
are consistent with the compound interfering with p65 DNA binding directly and not with the 
NF-κB activation steps. Recently, our lab obtained data confirming that pHPP inhibits activation 
of NF-κB using EMSA analysis (Meaghan E. Killeen, unpublished results). Further work to 
confirm modification of NF-κB by pHPP is currently awaiting funding. Pyruvate derivatives 
may also inhibit activation of NF-κB by scavenging ROS (126).  In addition ethyl pyruvate was 
shown to inhibit lipid peroxidation in vitro (127) and in vivo (128). pHPP is the first intermediate 
in tyrosine catabolism: it is converted to homogentisic acid, which is oxidized to 
maleylacetoacetate (MAA); maleylacetoacetic acid isomerase (MAAI) catalyzes the 
isomerization of MAA to fumarylacetoacetate, which is converted to fumarate and acetoacetate. 
This makes pHPP a suitable carbon source which could be important in inflammation when the 
energy sources are deprived.  
        Regardless of the underlying mechanism, further studies of the ability of pHPP to treat 
experimental inflammation seem warranted. Studies in a rat profound hemorrhagic shock (HS) 
model have shown that pHPP is superior to EP in extending survival time in the absence of 
resuscitation.   
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3.0  CHAPTER THREE - COMPARISON OF DISTINCT PROTEIN ISOFORMS OF THE 
RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS EXPRESSED IN TISSUES 
AND CELL LINES 
3.1 ABSTRACT 
The receptor for advanced glycation end-products (RAGE) is expressed as numerous protein 
isoforms. Northern blotting, immunoblotting and sensitivity to N-glycanase digestion were used 
to survey RAGE isoforms expressed in cell lines and mouse tissues to obtain a comprehensive 
view of the RAGE expressome. Pulmonary RAGE mRNA (1.4 kb) was smaller than cell line and 
tissue RAGE mRNA (6 kb-10 kb). Three anti-RAGE antibodies that recognize three distinct 
RAGE epitopes were used for these studies (N-16, H-300 and αES; see Fig. 21). Lung expressed 
four predominant protein isoforms with apparent molecular masses of 57.4, 52.6, 45.1 (N-16/H-
300) and 25 kDa (αES), and three less abundant isoforms at 46.9, 52.5 and 54.2 kDa (αES). 
These isoforms were expressed exclusively in lung, heart, ileum and kidney as a 44.0 kDa 
isoform (N-16), while aorta and pancreas expressed a 53.3 kDa isoform (αES). Each of these 
isoforms were absent in tissue extracts prepared from RAGE-/- mice. Cell lines expressed a 70 
kDa isoform and a subset expressed a 30 kDa isoform (αES). Lung RAGE appeared to contain 
two N-linked glycans, whereas tissue and cell line RAGE isoforms were completely insensitive 
to PNGase F digestion. Thus, numerous RAGE protein isoforms are detected in tissues and cell 
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lines. Canonical transmembrane and soluble RAGE appear to be expressed solely in lung (N-
16/H-300). Non-pulmonary tissues and cell lines, regardless of the source tissue, both expressed 
distinct RAGE protein isoforms containing the N-terminally located N-16 epitope or the αES 
RAGE epitope encoded by alternate exon 9, but not the H-300 epitope. Cell lines, of both 
pulmonary and non-pulmonary origins, were able to express pulmonary RAGE mRNA (1.4 kb) 
upon transfection with an expression plasmid containing the pulmonary full-length cDNA. 
However, only non-pulmonary cell lines (HEK 293 and HMEC-1) were able to express full-
length RAGE protein (H-300 antibody-positive, PNGase-sensitive). Lung-derived cell lines, 
including human A549, CaLu-3, and rat R3/1 failed to express canonical RAGE protein in spite 
of the fact that they expressed the transfected canonical RAGE mRNA at levels equal to HEK 
293 and HMEC-1. After evaluating a mouse EST (expressed sequence tags) database, we 
analyzed RAGE expression in the mouse thyroid. We confirmed that mouse thyroid expressed 
the same RAGE isoforms as lungs. They were H-300 antibody-positive and PNGase-sensitive. 
Thyroid however expressed only a small fraction of the RAGE protein levels expressed in lung.  
3.2 RESULTS 
3.2.1 In silico analysis of RAGE mRNA expression  
We examined RAGE mRNA expression by comparing the relative abundance of ESTs  in 
various human, mouse and rat tissues using the Gene Expression Omnibus repository at the 
National Center for Biotechnology Information (129) and the results are summarized in Table 2. 
Most notable is the over-representation of RAGE ESTs present in the lung of all three species. 
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This trend is also obvious in other mammalian species, but the analysis here is limited to human, 
mouse and rat. Only mouse thyroid expressed more RAGE transcripts than lungs. This 
information is not shown in an attempt to catalog the RAGE transcriptome, but it is included to 
highlight the notable exceptions where RAGE transcripts are expected but not well represented 
(e.g., brain 71, 72). 
 
Table 2. Relative number of EST clones per million identified in tissue and   species-specific databases (129). 
Table was last updated on 10/06/08. 
 
H. sapiens M. musculus R. norvigicus 
lung 139 thyroid 899 lung 682 
ear 61 lung 110 thymus 245 
connective 
tissue 
26 mammary gland 3 placenta 46 
heart 22 adipose tissue 0 eye 32 
lymph node 21 blood 0 brain 16 
eye 18 bone marrow 0 adipose tissue 0 
mammary 
gland 
12 brain 2 connective tissue 0 
thymus 12 connective tissue 0 dorsal root 
ganglion 
0 
ovary 9 dorsal root 
ganglion 
0 endocrine 0 
stomach 10 embryonic tissue 0 gastrointestinal 
tract 
0 
pancreas 9 eye 0 genitourinary 0 
intestine 4 female genital 0 head and neck 0 
prostate 5 gastrointestinal 
tract 
0 heart 0 
testis 6 head and neck 0 liver 0 
bladder 0 heart 0 muscle 0 
blood 0 inner ear 0 pancreas 0 
bone marrow 0 limb 0     
brain 0 liver 0     
kidney 0 lymph node 0     
liver 0 muscle 0     
lymph 0 pancreas 0     
 35 
muscle 0 prostate 0     
nerve 0 skin 0     
parathyroid 0 spinal cord 0     
skin 0 spleen 0     
small intestine 0 sympathetic 
ganglion 
0     
spleen 0 testis 0     
thyroid 0 thymus 0     
trachea 0 urinary 0     
vascular 0 vascular 0     
whole brain 0 vesicular gland 0     
 
3.2.2 Northern blot analysis of RAGE isoforms expression  
Northern blot analysis was performed to compare the size of RAGE transcripts expressed in 
various cell lines and tissues (Fig. 11). Total RNA was hybridized using an in vitro transcribed 
full-length human RAGE cRNA probe. Distinctly different hybridization patterns were observed 
when comparing lung, liver, brain, and pancreas. Lung expressed a major band of approximately 
1.4 kb and another much less prominent band of approximately 3.5 kb. One predominant band of 
approximately 6 kb was present in liver extracts. Two bands of higher mobility were also 
present, but they did not seem to correspond to the same size bands present in lung at the 
resolution achieved using agarose gels. Mouse brain expressed very low levels of what appear to 
be the 1.4 and 3.5 kb RAGE transcripts present in mouse lung but their presence is much less 
convincing. No bands were detected in pancreases that were homologous to the human mRAGE 
probe at the hybridization stringency used for these studies.   
Northern blot analysis of several human and mouse cell lines generated a common transcript 
pattern (Fig. 11B). Each cell line expressed an approximately 6 kb transcript of similar size to the 
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transcript observed in mouse liver. Cell lines also expressed a longer transcript that is also 
detectable in mouse lung at approximately 10 kb. We compared HEK293 cells transfected with 
RAGE cDNA with HEK293 transfected with the empty vector (Fig. 11C). RAGE-transfected 
cells obtained lung size transcript (1.4 kb) while still expressing the endogenous ones.  
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Figure 11. Northern blot analysis of mouse tissues and cell lines.  
Radiolabeled full-length cRNA was hybridized to size-fractionated total RNA on nylon filters. In mouse lung 
RAGE transcript was approximately 1.4 kb. Other tissues and cell lines expressed larger transcripts ranging 
from 4 to 10 kb (B). HEK293 transfected with the full size RAGE also express 1.4 kb isoform (C). This blot is 
representative of at least 3 experiments. 
3.2.3  H-300 and N-16 recognize distinct RAGE epitopes that are only present 
together in RAGE protein isoforms expressed in lung 
We compared the ability of two commercially available α-RAGE antisera to detect RAGE 
protein expression in various mouse tissues. H-300 and N-16 (Figs. 12A & 13B, respectively) 
each recognized bands in mouse lung lysate with apparent molecular masses of 57.4, 52.6 and 
45.1 kDa. H-300 failed to detect RAGE in other tissues, even after overexposing the film (not 
shown). In contrast, N-16 also detected a 51.2 kDa band in liver extract (Fig. 12B), and longer 
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exposures detected a 40 kDa band in heart and kidney extracts and an additional 34.5 kDa band 
in kidney extracts (Fig. 17). GAPDH is used as a loading control (Fig. 12C). Clearly, the lung 
isoform possesses all the epitopes that are believed to be in the RAGE protein, whereas other 
tissues only have the N-16-positive sequence. Thus, H-300 and N-16 clearly recognize different 
epitopes.  
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Figure 12. Western blots showing RAGE isoforms expressed in various mouse tissues.  
Equal amounts of protein (20 μg/lane, 10 μg/lane for the lung lysate) were fractionated using reducing SDS-
PAGE. H-300 and N-16 antibodies recognize the three major RAGE isoforms expressed in mouse lung lysate 
(A and B). H-300 only detected the mouse lung isoforms while N-16 recognized a single band in liver on this 
exposure. GAPDH was used as loading control (C). Western blot of the RAGE knockout mice probed with 
the N-16 antibody was used as a negative control (D). Wild type mouse lung (1 μg/lane) was used as a positive 
control. This blot is representative of at least 3 experiments. 
 
 
The αES polyclonal antiserum was raised against a unique peptide present in the esRAGE 
sequence that is not present in the transmembrane pulmonary RAGE isoform (106). This 
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antiserum detected four bands in lung protein extract with apparent molecular masses of 44.0, 
46.9, 52.5 and 54.2 kDa and a more intense band of approximately 25 kDa (Fig. 13A). αES 
detected numerous RAGE isoforms with various sizes that appear to be expressed in a tissue-
specific manner. Aorta expressed a strongly staining 53.3 kDa isoform that also appears to be the 
major RAGE isoform in pancreas and derma. αES also detected poorly resolved bands in aorta 
and derma in the 47 – 49 kDa region of the gel. Kidney and liver express unique proteins at 40.0 
kDa and 56.8 kDa. Liver also expressed 58.6 kDa and 54.2 kDa isoforms that were detected by  
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Figure 13. α−esRAGE antibody failed to detect canonical RAGE bands in Western blot analysis but detected 
numerous bands of various mobilities.  
Western blot analysis showing RAGE protein in the engineered RAGE -/- mice was used as a negative 
control. Each organ is represented by two different mice. Both blots were probed with the anti-esRAGE 
antibody. Each lane contained 20 μg of total protein. This blot is representative of at least 3 experiments. 
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αES. All tissues, except spleen, express a 45kDa αES band. It is important to note that none of 
the bands recognized with the αES antiserum were also recognized by either the N-16 or the H-
300 antisera.  
We prepared and analyzed protein extracts from tissues obtained from engineered RAGE-/- 
mice (105, 130-132) kindly provided by Dr. Oury. H-300 (data not shown) and N-16 failed to 
detect proteins in any of the tissues obtained from knockout mice (Fig. 12D). Most of the bands 
recognized by αES in RAGE+/+ tissue extracts were absent in extracts from RAGE-/- tissue (Fig. 
13A&B). However, αES detected a 44.0 kDa protein in heart and kidney extracts obtained from 
RAGE-/- mice. Lung and liver extracts from RAGE-/- mice did not contain the 44.0 kDa protein.  
The relative reduction in the expression of this protein in heart and kidney suggests that some of 
the signal in wild-type mice represents a unique esRAGE isoform, but this will need to be 
confirmed using higher resolution studies. 
3.2.4 Mouse lung RAGE isoforms 
We refer to the 57.4, 52.6 and 45.1 kDa proteins recognized by N-16 in lung lysate as xRAGE, 
membrane (m)RAGE, and soluble (s)RAGE, respectively. Expression of the xRAGE isoform 
increased following injection of mice with endotoxin (2 mg/kg, given by ip injection; Fig. 14). 
Mice injected with saline vehicle typically expressed low to undetectable amounts of the xRAGE 
protein isoform in the lung. We used the method described by Hanford et al. (61) to confirm that 
both xRAGE and mRAGE were membrane bound and sRAGE was not (data not shown).  
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Figure 14. Western blots analysis of mouse pulmonary RAGE isoforms expressed following injection of 
C57BL6 mice with 2 mg/kg of LPS at the times indicated (time course).  
10 μg of total protein were fractionated per lane using reducing SDS-PAGE and GAPDH was used as loading 
control. This blot is representative of at least 3 experiments.  
 
 
Mass spectroscopy (MS) was used to confirm that the inducible 57.4 kDa protein is a RAGE 
protein isoform. xRAGE was captured from mouse lung protein lysate using a DEAE Sepharose 
column as was done previously (48, 61) (Fig. 15A). Analysis of column fractions by Western 
blotting with N-16 demonstrated enrichment of xRAGE and mRAGE in Step II. These fractions 
were pooled and subjected to affinity chromatography on concanavalin A lectin agarose and 
Mono Q anion exchange beads. The highly enriched proteins were size-fractionated using SDS-
PAGE (Fig. 15B) and subjected to in-gel trypsin digestion. MALDI-TOF MS spectral analysis of 
xRAGE (Fig. 15C) identified eight peptide fragments resulting in 22% sequence coverage based 
on the pulmonary mRAGE protein sequence (Fig. 15D). Identical peptides were obtained from 
the mRAGE MS analysis (data not shown). No information was obtained concerning the 
apparent molecular mass difference between the xRAGE and mRAGE isoforms.  
 41 
pump mixture (%B)
m
ill
ia
bs
or
ba
nc
e 
un
its
 (2
80
 n
m
)
ml
FT
I II
conductance (mS/cm)
A B
DEAE Pool
X
M
S
M
LL
S M
96
51
37
I
II
C
X
M
 
 
100 200 4020 300
Exp The Δ Da Start End Sequence 
1468.796 1468.819 -0.02 30 43 IGEPLVLSCKGAPK 
1153.658 1153.636 0.02 44 52 KPPQQLEWK 
2552.311 2552.361 -0.05 116 139 VYQIPGKPEIVDPASELTASVPNK
1325.787 1325.804 -0.02 162 173 LLIPDGKETLVK 
1326.764 1326.728 0.04 178 188 RHPETGLFTLR 
1170.658 1170.627 0.03 179 188 HPETGLFTLR 
1434.903 1434.865 0.04 216 227 RRPLNTAPIQLR 
1278.797 1278.764 0.03 217 227 RPLNTAPIQLR 
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Figure 15. Purification and confirmation that xRAGE is an authentic RAGE isoform.  
Lungs were prepared from 6 endotoxemic mice and lysed using RIPA buffer. This was diluted 1:1 in Buffer A 
(20 mM Tris, pH 7.5, 50 mM NaCl, 1% CHAPS, and 1 mM DTT) and applied to a DEAE Sepharose CL4B 
column (40 ml). Proteins were step eluted with 220 mM NaCl (Step I) and 460 mM NaCl (Step II) (A). 
xRAGE was detected in fractions by Western blotting and was enriched in Step II. This material was bound 
to a concanavalin A agarose column (10 ml), washed extensively until the eluent was within 2% of baseline 
absorbance, and eluted with 15 ml of 0.5 M methylmannopyranoside. The eluted material was concentrated 
and size-fractionated using SDS-PAGE (B). The xRAGE band was excised, subjected to in gel digestion with 
trypsin. Mass spectra were obtained (C) that contained several peptides (D) encoded by the mouse RAGE 
gene.  
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3.2.5 RAGE isoforms in mouse cell lines 
Protein extracts were prepared from several mouse-derived cell lines including enterocyte-like 
CMT-93, pneumocyte-like LA-4, renal mesangial-like MES-13, pulmonary fibroblast MLF, 
embryonic kidney epithelial NIH 3T3, macrophage-like RAW 264.7 and adrenal cortical Y1 
cells. Equal amounts of protein were subjected to Western blot analysis (Fig. 16). Mouse lung 
lysate is included for comparison. N-16 detected a single 50 kDa band in CMT-93 cells while the 
other cell lines were negative for N-16 staining. H-300 antibody failed to detect any bands in any 
of these cell lysates (data not shown). αES antibody detected an approximately 43.2 kDa isoform 
in each cell line. All cell lines, except Y1 adrenal cells, also expressed an esRAGE isoform with 
apparent molecular weight of 69.4 kDa. Additional lighter bands were also apparent in several 
cell lines.  
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Figure 16. Comparative Western blot analysis of representative established mouse cell lines.  
Cell lysates prepared in RIPA buffer were resolved on the SDS-PAGE gel system and probed with the 
indicated antibody. This blot is representative of at least 3 experiments.  
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3.2.6 Protein N-glycosylation of RAGE protein isoforms 
The primary mouse RAGE sequence predicts two N-glycosylation sites,  and this was confirmed 
experimentally for the lung canonical transmembrane (49) and soluble (61) RAGE isoforms. 
PNGase F digestion was used to compare N-glycosylation of various RAGE protein isoforms. 
xRAGE, mRAGE and sRAGE isoforms expressed in mouse lung lysate showed increased 
mobility on SDS-PAGE of approximately 3.4 kDa following PNGase F treatment (Fig. 17). This 
difference is consistent with the removal of two N-linked glycans of approximately 1.7 kDa 
each. RAGE isoforms identified in non-lung tissues using N-16 (Fig. 17) and αES (Fig. 18) were 
insensitive to PNGase F digestion. This is important as these bands are not present in tissues 
from RAGE knockout mice (see Fig. 12) which supports our contention that non-lung tissues 
express a RAGE isoform with a distinct protein sequence compared to canonical pulmonary-
thyroid RAGE. The implications of this for ligand recognition and subsequent signal 
transduction remain to be determined. RAGE isoforms detected with N-16 in human HEK 293 
(Fig. 18), A549 and HMEC-1 (data not shown) cell lysates were insensitive to PNGase F 
digestion, suggesting that it they were not N-glycosylated. In support of this finding, RAGE from 
the human enterocyte-like Caco-2 cell line was similarly not N-glycosylated (133).   
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Figure 17. Mouse deglycosylation pattern of RAGE isoforms.  
Mouse tissues indicated were homogenized in RIPA buffer and subjected to PNGase F digestions followed by 
Western blot analysis. Digested samples were run alongside with the undigested protein lysates. We used 25 
μg per lane for all the tissues except for the lung where we used 12 μg. N-16 antibody was used to probe the 
membrane. This blot is representative of at least 3 experiments.  
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Figure 18. Comparative deglycosylation analysis of the mouse lung lysate.  
HEK293 and HEK293 transfected with full-length RAGE. Control and PNGase digested samples were 
subjected to Western blot analysis. Notice that PNGase F does not affect migration of the endogenous RAGE 
band in both HEK293 and HEK293 transfected with the full-length RAGE. Transfected RAGE protein 
migrated similarly to the lung isoform. N-16 antibody was used to probe the membrane. This blot is 
representative of at least 3 experiments. 
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3.2.7 Non-pulmonary cells transfected with the lung RAGE cDNA express and N-
glysosylate the canonical pulmonary membrane RAGE protein isoform 
Transient transfection of HEK 293 (Fig. 18) and HMEC-1 (data not shown) cells with a human 
mRAGE cDNA expression vector (106) caused accumulation of a transcript the size of the 
predominant RAGE mRNA species expressed in mouse and human lung. Transfection with the 
empty vector was used as a negative control. Expression of the endogenous cell line RAGE 
transcripts did not change in transfected cells (Fig. 11). Transfected HEK 293 cells expressed a 
protein with the same mobility as pulmonary mRAGE (Fig. 18). Ectopically expressed 
pulmonary mRAGE was sensitive to digestion with PNGase F, increasing protein mobility by 
approximately 3.4 kDa. Expression of the endogenous cell line RAGE isoform that is detected 
with N-16 remained unchanged following exposure to PNGase.  
3.2.8 Pulmonary cell lines transfected with full-length RAGE express mRNA but 
no detectable protein 
We transfected three lung-derived cell lines (A549, CaLu-2, R3/1) with the full-length RAGE 
cDNA plasmid. Although their RAGE mRNA levels were significantly elevated (data not 
shown), we failed to detect any full-length RAGE protein (Fig. 19). Endogenously expressed 
RAGE protein isoforms remain unchanged.  
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Figure 19. Lung-derived cell lines transfected with full-length RAGE do not express canonical RAGE protein. 
A549 and CaLu-3 cell lines were transfected according to the protocol. The cells express cell line endogenous 
RAGE isoform which stays unchanged after transfection. This blot is representative of at least 3 experiments. 
Western blot was used to access RAGE protein expression in 48 h.       
3.2.9 Lung RAGE is N-glycosylated in mouse, human, rat and cow  
N-glycosylation of lung RAGE is also found in human, cow and rat (Fig. 20 and unpublished 
observations). We performed a comparative deglycosylation analysis of RAGE isoforms in the 
above species. In mouse, rats and cows, only lung RAGE had two N-glycans, isoforms from 
other tested organs had none; in human lung RAGE could have three N-glycans and other tissues 
appear to have 1. Taken together our data suggest that lung RAGE differs from RAGE in other 
tissues in different species.  
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Figure 20. Comparative deglycosylation analysis of human and bovine tissues.  
Control and PNGase F digested samples were subjected to Western blot analysis. Lung RAGE isoforms 
appeared to have more N-glycans in human and to be the only N-glycosylated isoform in cow. N-16 antibody 
was used to probe both membranes. This blot is representative of 2 independent experiments. 
3.2.10 Mouse thyroid expresses the same RAGE isoforms as lungs 
In Section 3.2.1, we showed that mouse thyroid expressed far more RAGE EST transcripts than 
lung. This, however, was true only for the mouse. Human and rat tissues did not follow the same 
trend. We analyzed mouse RAGE isoforms from thyroid in terms of antibody reactivity and 
PNGase sensitivity. To our surprise, we confirmed that mouse lung and thyroid indeed expressed 
the same RAGE isoforms. This finding was based on the antibody reactivity (H-300 antibody 
only identifies pulmonary RAGE) and PNGase sensitivity (Fig. 21). The same thyroid RAGE 
isoforms were also detected by N-16 antibody (data not shown). Thyroid, however, expressed far 
less RAGE protein then could be predicted from the EST transcript database (compare Table 2 
and Fig. 21).   
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Figure 21. Comparative deglycosylation analysis of RAGE isoforms from mouse thyroid and lung.  
Control and PNGase F digested samples were subjected to Western blot analysis. Thyroid and lung RAGE 
isoforms appeared to have very similar sizes and N-deglycosylation patterns. Those are also only two on 
known to us organs that can be recognized by H-300 antibody which was used to probe the membrane. This 
blot is representative of 2 independent experiments. 
 
3.3 DISCUSSION 
Several conclusions can be drawn from these findings. First, of the tissues examined, lung 
expressed the highest levels of RAGE mRNA and protein. Second, in mice, the canonical 
transmembrane RAGE isoform (mRAGE) that was originally identified by Schmidt and 
colleagues in bovine lung extracts appears to only be expressed in lung and is detected by both 
H-300 and N-16. Third, transfection of cells with a pulmonary mRAGE cDNA expression vector 
permitted expression of an N-glycosylated pulmonary RAGE isoform (Figs. 10 & 17) showing 
that these cells are capable of protein N-glycosylation. This is important since the endogenous 
cell line RAGE isoforms were not N-glycosylated. Fourth, the RAGE-gene encoded αES epitope 
was absent in RAGE-/- mice and was expressed in all tissues examined. However, the αES 
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epitope is not detectable in RAGE protein isoforms containing an N-16 or H-300 epitope, as is 
predicted by published mRNA sequences (67, 106) and Fig. 22. The inclusion of intron 9 in the 
esRAGE mRNA was predicted to result in early translation termination due to an in frame STOP 
codon. Therefore, these authors have assumed incorrectly that sequence upstream of the αES 
epitope is the same as canonical RAGE. 
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Figure 22. Cartoon showing positions of the N, H and ES immunogens used to generate the antisera.  
While the canonical RAGE protein sequence is well established our data suggest that epitopes in N and H 
peptides are only co-expressed in lung RAGE isoforms. RAGE isoforms containing only the N epitope were 
identified. ES RAGE protein isoforms were detected but they were not co-expressed with the N or H epitopes 
as was proposed (67, 106). SP and TM stand for signal peptide and transmembrane domain, respectively. 
 
The consequences of these studies are apparent when one considers them in light of data 
reported in the original manuscript by Schmidt and colleagues (48). An AGE-binding assay 
using newborn calf aortic endothelial cells was employed to assay fractions for the presence of 
AGE-binding proteins. Given that lung is about 50% endothelial cells and 50% epithelial cells 
(134), bovine lung served as a logical source material for their needs. A novel 35 kDa AGE-
binding protein was identified using NH2-terminal Edman degradation. Reverse translation of 
this sequence facilitated the cloning of the bovine cDNA which encodes a 44 kDa protein 
(GenBank NP_776407, refs 48, 49). The discrepancy between the predicted molecular weight is 
rather large and was not simply a resolution artifact of the gels. Subsequent studies by others 
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clearly show that the major site of expression of RAGE in lung is type I epithelial cells (33, 53). 
The bovine RAGE isoforms reported in studies of type I cells by Schmidt and colleagues are 
probably homologous to those recognized in Western blots of mouse, human and cow lung 
probed with H-300 (Fig. 12A&21). Figure 3A of reference 1 shows AGE-binding activity of 
fractions eluting from a hydroxylapatite column. Fractions with the highest AGE-binding activity 
were further purified for sequence analysis. This represented only 10% of the total AGE-binding 
activity applied to the column. We feel a significant proportion of the AGE-binding activity that 
did not co-elute with the 35 kDa bovine RAGE represents, at least in part, the N-16 and esRAGE 
isoforms expressed at significantly lower levels in the numerous additional cell types present in 
the lung. Thus, it is entirely possible that the AGE-binding activity present on the endothelial 
cells used in the identification of pulmonary mRAGE was actually a related esRAGE isoform.  
Alternatively, it may also be the bovine homologue of the non-N-glycosylated isoform 
recognized at low levels by N-16 that runs at 48 kDa in human cell lines and in the CMT-3 
murine cell line. Additional studies are warranted to answer this important question. 
Numerous esRAGE isoforms expressed in mouse lung may actually be expressed by a 
variety of cells including type I cells, alveolar macrophages and endothelial cells of smaller 
branching arteries and other components of the pulmonary tree. Our studies of mouse (Fig. 17) 
and human aorta and HMEC-1 cells (135) failed to detect the N-glycosylated mRAGE isoform 
that appears to be exclusively expressed in lung and thyroid. However, RAGE-gene derived 
protein isoforms that arise through alternative splicing of exon 9 which encodes the “es” epitope 
in mouse and human (106) are clearly present in mouse aorta and HMEC-1 cells.  
We have seen that most cell lines express a cell line isoform of RAGE as determined by 
Northern (Fig. 11) and Western blotting (Figs. 6 & 8 and ref 135) and do not express the 
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endogenous full-length isoform expressed predominantly in lung and to a lesser extent in thyroid. 
Thus, these cells are not RAGE-negative, so the value of establishing a RAGE signaling pathway 
using them is suspect. Only when lung RAGE cDNA was expressed in cultured cell lines did 
they expressed full-length RAGE, suggesting that a special cellular environment is required. 
Hyporoxia could be one of the factors as it was shown to alter expression and phosphorylation of 
translation initiation factors in lung and enhance their affinity for inhibitory proteins (4E-BP1). 
This ultimately resulted in the diminished protein synthesis (136). Lung RAGE might require 
specific oxygen concentrations to be expressed. RAGE also might need lung-specific 
transcription activators. For instance, expression of two forkhead related activator proteins 
(FREAC-1 and 2) is restricted to lung and placenta. Promoters of lung-specific genes (surfactant 
proteins A, B, C, and the Clara cell 10 kDa protein (CC10)) contain potential binding sites for 
FREAC-1 and FREAC-2. In the experiments with the cell lines FREAC-1 and FREAC-1 
activated transcription of the lung-specific genes (137). Later we discuss TTF-1, which also 
appears to be lung and thyroid-specific. When non-lung cells are transfected with the lung-
specific RAGE, they might also express downstream signaling molecules that are specific for the 
RAGE isoforms expressed in cell lines and might be missing some elements only expressed in 
type I pneumocytes in situ.  
Additional support for our belief that the non-lung RAGE isoforms are RAGE is as follows. 
In mouse, organs expressing detectable RAGE protein other than lung included heart, kidney and 
liver (Figs. 2 & 8). To get blots to work we needed to decrease stringency by decreasing the 
Blotto concentration and using longer exposure times. This may create a problem with 
specificity, however these bands were absent on Western blot from RAGE knockout mice. 
Additional confirmation is needed in the form of protein primary sequence which is the focus of 
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future studies. esRAGE isoforms expressed in these tissues were not N-glycosylated. Moreover, 
when we analyzed extracts derived from RAGE knockout animals, we only detected a single 
protein band on Western blot using αES, suggesting that all other bands on that gel were in fact 
derived from the RAGE gene.  
Our results are clearly incongruous with numerous publications describing “RAGE” 
expression in multiple animal tissues. We feel a major reason for this discrepancy comes from 
the fact that investigators assayed RAGE expression using tissue immunostaining (138) and 
ELISA (139). Importantly, Western blotting was not used; therefore, no conclusions should be 
made concerning isoform size and the extent of N-glycosylation. More importantly, we have data 
that suggests that canonical RAGE is no expressed at all in non-lung/thyroid tissues during 
normal and inflamed states. This is however the point that many of these authors are trying to 
make (i.e. that “RAGE” is expressed). Immunostaining alone cannot distinguish between RAGE 
isoforms. Significant information was obtained in our Northern blot studies. Clearly different 
mRNAs encode the distinct RAGE isoforms in mouse lung and thyroid, non-lung, and cultured 
cells.  In rats and dogs, full-length mRAGE is only present in the lung (50, 59). It appeared on 
the Northern blot as a clear 1.4 kb signal in mouse and human total RNA (Fig. 11). This band is 
clearly absent from non-lung tissues (thyroid was not tested) and all cell lines, and we feel it 
represents RNA encoding of the H-300 and N-16 epitopes of RAGE.  These data also suggest 
that the other RAGE-gene derived protein isoforms are clearly encoded by distinctly different 
mRNA. 
In mouse lung, in addition to the two pulmonary mouse RAGE isoforms, an isoform was 
observed, which we designated xRAGE, which is induced in mice injected with endotoxin. It 
appears at 1 h post-treatment and remains elevated until at least 24 h. We were unable to obtain 
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complete sequence coverage for the xRAGE isoform; yet we confirmed that this was indeed a 
RAGE isoform using MS. Several possibilities exist: first, xRAGE could represent cell 
population of RAGE precursor still caring signal peptide; LPS could cause an increase in RAGE 
production due to NF-κB activation and the cells don’t process it fast enough.  Second, RAGE 
might go through some post-translational modification(s) to become xRAGE. We don’t think 
that it involves N-glycosylation, because all three RAGE isoforms carried 2 N-Glycans that were 
removed by PNGase F (Fig. 18).  However, other post-translational modifications that were not 
addressed (acetylation, amidation at C-terminus, modification by covalent attachment of the 
small ubiquitin-related modifier (SUMO), and many others) are plausible. Such modification 
could serve as a part of inflammatory response of the cell. As of now, we know very little about 
the exact nature of xRAGE, further investigations are needed to better understand the regulation 
of its expression and the role in the lung.  
We evaluated RAGE isoforms expressed in different tissues and cell lines. Mouse organs, 
other than the lung and thyroid, and cell lines expressed distinctive RAGE isoforms which are 
not N-glycosylated and most likely have different primary sequences. The same is true about 
human, cow and rat. The RAGE isoform expressed in a particular tissue or cell line appears to 
depend upon the cell type and the cellular microenvironment. The reasons why thyroid expresses 
the same RAGE isoform as lung are currently unclear as are the exact mechanisms underlying 
the regulation of RAGE protein expression in general. Taken together, the data indicate complex 
expression and kinetics of RAGE isoforms with the undetermined role for each one of them in 
ligand recognition and signaling.  
Based on these observations, we hypothesize that lung- and thyroid-specific RAGE isoforms 
are different not only structurally, but also functionally. The selective and relatively high level of 
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mRAGE expressed in type 1 alveolocytes suggests an important and underappreciated role for 
these protein isoforms in pulmonary homeostasis. This is supported by the fact that RAGE-null 
animals are more susceptible to the idiopathic pulmonary fibrosis (60). RAGE was found to play 
a crucial role in cell attachment to the basement membrane through collagen IV (33). 
Furthermore, N-glycosylation, which is specific to the pulmonary and thyroid RAGE, is very 
important in ligand recognition (140). The lung tissue microenvironment is able to drive the 
specific splicing/proteolytic events that are required for specific lung RAGE isoform synthesis.  
In conclusion, we attempted to make sense of the numerous studies of RAGE isoform 
expression that have been published to date; we investigated the topic using a broad approach to 
examine RAGE isoform expression. We were able to identify thyroid as an organ expressing the 
same RAGE isoforms as lung using EST database. Thyroid RAGE isoforms appear to have the 
same molecular weights and deglycosylation patterns (two N-glycans) as the pulmonary 
isoforms. The respiratory system, along with thyroid and other organs (pancreas, liver etc.), 
arises from the ventral foregut endoderm which differentiates into various epithelial cell types 
(141). In addition, lung and thyroid progenitors could be identified in embryo at day 9 (E9) by 
expression of thyroid Nkx2.1 expression. Nkx2.1 is also known as thyroid transcription factor 1 
(TTF-1). Nkx2.1 knockout mice have lungs, but they are highly abnormal (142). They consist of 
cystic structures lined by columnar cells with scattered cilia similar to those found in proximal 
airways. So, Nkx2.1 was found to be crucial in distal (alveolar) airway development (142). Also, 
Nkx2.1 could play a role in the epithelial-mesenchymal interactions based on the finding that 
collagen type IV and several integrins were extremely deficient in the Nkx2.1-null animals 
(143). Interestingly, collagen IV was found to preferentially interact with RAGE proteins in the 
RAGE-transfected HEK 293 cells, making it crucial for cell spreading and morphology (33). 
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Nevertheless, thyroid RAGE isoforms are not expressed at the high lung levels despite the 
abundance of RAGE transcripts. Further investigations are needed to elucidate the significance 
of canonical RAGE in the tissue. We feel this “forest for the trees” view will be helpful in 
designing future studies of RAGE isoform expression in particular, as well as assist investigators 
in designing and interpreting studies of RAGE function in general.  
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4.0  CHAPTER FOUR – RESPONSE TO THE RAGE LIGANDS IN VARIOUS TISSUES 
AND CELL LINES 
4.1 ABSTRACT 
RAGE was purified and sequenced from bovine lung extract 17 years ago, but the exact 
mechanisms of its signaling are still unclear. It is thought to involve ERK-1/2 kinases, p38, 
SAPK/JNK kinases, rho-GTPases, phosphoinositide 3-kinases, JAK/STAT pathway, and NF-κB 
(43). One publication reported direct binding of ERK to RAGE, however those observations 
were made in RAGE-transfected cells (88). There is a whole body of literature debating the 
signaling events taking place following stimulation with “RAGE” ligands. Some of these false 
positive effects are explained by not using the appropriate controls (BSA with AGEs) or 
contamination of the “RAGE” ligands with LPS. In our hands, the human microvascular 
endothelial cell line (HMEC-1) was responsive to the “RAGE” ligands S100B and HMGB1.  
S100B upregulated monocyte chemotactic protein 1 (MCP-1) expression whereas HMGB1 
downregulated it in a dose-dependent manner. When applied together, HMGB1 abrogated 
S100B-mediated effects. This trend did not change when HMEC-1 were transfected with full-
length RAGE. All other utilized cell types, including two lung-derived lines, did not respond to 
the “RAGE” ligands when we assayed for NF-κB activation and MCP-1 expression. HEK 293 
cells did not respond to “RAGE” ligands even after being transfected with the plasmid encoding 
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the full-length RAGE sequence. When we used mouse lung slices (MLS) as a system expressing 
canonical full-length lung RAGE, we did not register a response from the “RAGE” ligands using 
these same assays. However, RAGE expression seemed to be important for the inflammatory 
response caused by LPS and IL-1β. When comparing MLS from RAGE knockout mice to the 
wild-type controls, LPS-induced MCP-1 expression was consistently higher in the wild-type 
mice. These didn’t seem to suggest that lung RAGE plays a role in the inflammatory response. 
We also concluded that in cell lines, “RAGE” ligands do not apparently signal through RAGE, 
but through other receptors. 
4.2 RESULTS 
4.2.1  “RAGE” ligands do not activate NF-κB in A549, HMEC-1 and HMEC-1 
transfected with the full-length RAGE  
NF-κB is believed to take part in RAGE signal transduction. Two cell lines available to us were 
tested. These were human A549 cells, which were derived from lung, and HMEC-1, a human 
microvascular endothelial cell line (144). Since we were unable to detect canonical RAGE when 
the full-size RAGE cDNA was transfected into lung-derived cell lines (Section 3.1.8), we only 
used transfected HMEC-1 cells for some studies. NF-κB binding was analyzed upon application 
of ‘RAGE’ ligands including AGEs, S100B and HMGB1 to A549, HMEC-1 and HMEC-1 cells 
transfected with the full-length RAGE. IL-1β was used as a positive control for the assay. We 
failed to observe increased NF-κB binding when we applied “RAGE” ligands (Fig. 23). This was 
surprising since many publications suggest that a lot of cellular responses to RAGE ligands are 
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mediated, at least in part, by NF-κB. When we exposed HMEC-1 cells to IL-1β we observed 
nuclear translocation of NF-κB, confirming the integrity of that pathway in these cells. 
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Figure 23. NF-κB activation in sample cell lines.  
EMSA was performed in A549 (lung-derived cell line) and HMEC-1 (non-lung derived cell line). HMEC-1 
cells were transfected with the full-length RAGE and with the vector. A549 do not express full-length RAGE 
when transfected therefore transfected cells were not used (Section 3.1.8). Cells were assayed 30 min after 
stimulation.  IL-1β was used as a positive control. This blot is representative of 3 independent experiments. 
4.2.2 “RAGE” ligands alter MCP-1 mRNA expression in the HMEC-1 cell line: 
S100B induces and HMGB1 suppresses it  
MCP-1 mRNA was reported to be induced by S100B in HMEC-1 cells  using microarray 
analysis (78). We used S100B as well as HMGB1 and AGEs and measured MCP-1 mRNA as a 
readout. While we were unable to see any effect caused by AGEs, we registered a dose-
dependent increase of MCP-1 mRNA induced by S100B. HMGB1 alone decreased MCP-1 basal 
levels. When added together, HMGB1 abrogated S100B-stimulated effects (Fig. 24).  
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Figure 24. MCP-1 mRNA dose response to increasing concentrations of S100B (A) and HMGB1 (B).  
HMEC-1 cells were grown and stimulated as described. MCP-1 steady-state mRNA was measured in 18 h.  
using real time RT-PCR. Interestingly, HMGB1 appears to inhibit S100B induction of MCP-1 mRNA 
expression (C). Result are presented as means±SD (N=3). 
4.2.3  Anti-RAGE antibody (N-16) inhibits MCP-1 upregulation by post-induction 
repression  
HMEC-1 cells were pretreated with anti-RAGE antibody (N-16) for 10 min in an attempt to 
inhibit responses to S100B. When MCP-1 mRNA was measured using RT-PCR, no response 
was registered as a result of S100B treatment. This was also true for IL-1β  that was used as a 
positive control (Fig. 25A). In our hands anti-RAGE antibody was capable of inhibiting both 
S100B and IL-1β responses despite the fact that IL-1β is not a RAGE ligand. We then decided to 
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treat cells with anti-RAGE antibody alone to eliminate its direct effects on the cells (Fig. 25B). 
We registered MCP-1 response early (2 h), and it returned to baseline levels by 24 h time point. 
This is consistent with anti-RAGE antibody stimulating the cells by itself. We hypothesized that 
N-16 could cause dimerization of RAGE thus activating it. After the initial stimulation cells were 
not able to respond to other pro-inflammatory stimuli. 
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Figure 25. Anti-RAGE antibody (N-16) inhibits MCP-1 mRNA upregulation by S100B and IL-1β (A) as 
measured by MCP-1 mRNA increase (real time RT-PCR) in HMEC-1 cells.  
HMEC-1 cells were pretreated with N-16 anti-RAGE antibody 10 min prior to applying RAGE ligands. 
MCP-1 mRNA was measured with real time RT PCR 18 h later as a respond (A). In B HMEC-1 cells are 
responding to N-16 antibody alone; BST-1 was used as an unrelated control. N-16-mediated response is 
completely gone by 24 h. This experiment  was repeated twice. 
    
4.2.4  “RAGE” ligands failed to stimulate A549 and HEK 293 cell lines 
Since we were able to measure an affect caused by RAGE ligands in HMEC-1 cells, we sought 
to examine other cell types, especially those derived from lung. Lung appears to express the 
majority of RAGE as compared to other tissues, and the full-length RAGE isoform is unique to 
the lung (See Chapter 3). A549 is a human lung-derived cell type and HEK 293 is an epithelial 
type, derived from the human embryonic kidney. Both cell lines failed to express MCP-1 mRNA 
changes following stimulation with RAGE ligands, while IL-1β, which was used as a positive 
control, induced MCP-1 expression (Fig. 26). Among all tested cell lines, including two derived 
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from lung, HMEC-1 was the only line that responded to “RAGE” ligands using NF-κB or MCP-
1 expression as read-outs.  
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Figure 26. MCP-1 expression in A549 cells in response to the “RAGE” ligands.  
A549 cells were grown and stimulated as described and assayed 18 h later. MCP-1 steady-state mRNA was 
measured 18 h later with the real time RT PCR. Experiment was done twice. 
4.2.5 “RAGE” ligands fail to stimulate mouse lung slices (MLS), but RAGE is 
important in the inflammatory response to LPS and IL-1β  
In our experiments, we were unable to find a cell line or tissue other than lung that expresses the 
RAGE receptor originally sequenced from bovine lung (48) (See Chapter 3). Consequently, the 
MLS in vitro system was used to test “RAGE” ligands. MLS express lung RAGE ex vivo for at 
least a week (data not shown). As for HMEC-1 cells, we used MCP-1 as a readout. We were 
unable to measure any response to the “RAGE” ligands that were different in wild-type 
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compared to RAGE knockout mice. However, the inflammatory response to LPS and IL-1β was 
consistently lower in the knockout animals compared to wild-type (Fig. 27). Based on this 
observation, we concluded that these ligands do not use RAGE receptor in this system. Complex 
inflammatory responses to LPS and IL-1β, on the other hand, were not complete without RAGE. 
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Figure 27. MCP-1 expression in mouse lung slices (MLS) following exposure to pro-inflammatory factors in 
wild type and RAGE knockout mice.  
MCP-1 mRNA steady-state levels were measured with the real time RT PCR at 4 h (A) and 24 h (B). 
Experiment was repeated at least two times. 
4.2.6 Mouse lung slices from RAGE knockout mice express less IL-6 and MCP-1 
mRNA after LPS stimulation 
In addition to real time RT-PCR we used the Luminex™ cytokine assay to measure 
levels of 20 cytokine mRNA per sample. Luminex™ technology does not require an 
amplification step. We wanted to compare cytokine expression of genes in wild-type and RAGE 
knockout mice in response to LPS.  We analyzed mRNA levels at 24 h time point. IL-6 and 
MCP-1 mRNA were clearly different when comparing wild-type and knockout mice. It is 
possible that early responding cytokines (TNFα) were different as well; we are planning to 
analyze them in the future. In our hands two different assays (real time RT-PCR and Luminex™) 
showed differences in inflammatory response between wild-type and RAGE knockout mice. 
Further studies of signaling cascades are necessary.   
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Figure 28. Luminex™ cytokine assay in MLS. 
 Mice were sacrified by intraperitoneal injection of sodium pentobarbital, lungs were excised and MLS were 
prepared (see Methods).  LPS was applied to the lung tissue cultures after 1 h in culture. MLS were lysed at 
24 h and RNA was extracted according (see Methods). Each condition was assayed in triplicate. 100 μg of 
total RNA was assayed for inflammatory cytokines and chemokines using the BioSource International Mouse 
20-plex Luminex™  beadset. The results were normalized to β-actin. IL-6 (A) and MCP-1 (B) mRNAs were 
different between wild-type and knockout mice. Results are presented as means±SD (N=4 per conditions). 
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4.3 DISCUSSION 
Our signaling experiments do not cover all aspects of RAGE signaling. However, we tried to test 
most of the reported RAGE readouts. Among the cell lines tested, only HMEC-1 was responsive 
to S100B and HMGB1 in a dose-dependent manner when MCP-1 was used as a readout. At the 
same time, we failed to measure NF-κB activation in those cells, so S100B and HMGB1 
signaling appear to utilize NF-κB. N-16 recognize a RAGE isotope in HMEC-1 so we tried to 
block signal with αRAGE antibody. The experiment produced the expected results for S100B 
but not for IL-1β which does not signal through RAGE. It was therefore hypothesized that N-16 
was stimulating cells by dimerizing the RAGE receptor and that this prevented them from 
responding to other pro-inflammatory stimuli, which is known as post-induction repression. 
When we exposed HMEC-1 cells to the anti-RAGE antibody, we saw a strong early response 
(MCP-1 mRNA) that completely disappeared by 24 h. We are planning digest N-16 RAGE 
antibody with papain to obtain monomeric Fab fragment antibody preparation. This would allow 
us see if the Fab fragment alone would cause cell activation. We don’t expect to activate the cells 
because we will not dimerize RAGE receptor.  
We will then crosslink antibody fragment with anti-Fab antibody and measure MCP-1 
mRNA expression. We would expect constituently increased MCP-1 expression with no impact 
from IL-1β.  Further experiment would be needed to clarify RAGE signaling cascade. 
Although other cell lines appear to express a ‘cell line’ RAGE isoform, they do not respond 
to “RAGE” ligands when tested using accepted RAGE-dependent responses. Each “RAGE” 
ligand is able to bind receptors other than RAGE, so it is possible that S100B and HMGB1 
employ other signal cascades in HMEC-1 cells.  
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Our laboratory has published data of CaCo-2 cells permeability and how HMGB1 affected it 
(145). CaCo-2 cells are grown on transwells and are commonly used as a model of intestinal 
permeability. It is widely used for drug absorption, metabolism and toxicity (146). As expected, 
HMGB1 increased permeability of CaCo-2 monolayers as measure by FD4 clearance. It also 
increased NO· production in the cell supernatants. Anti-RAGE antibody (N-16) significantly 
reduced both effects of HMGB1. Unrelated antibody (raised against myosin light chain) did not 
have any effect on both permeability and NO· production; however, IL-1β positive control 
experiment was not done. Based on the HMEC-1 data we now think that anti-RAGE antibody 
could have prevented IL-1b hyperpermeability and NO· production despite the fact that IL-1β 
signaling has not been shown to depend on RAGE. We hypothesize that it could utilize the same 
mechanisms we discussed earlier (post-induction repression). It is important to use positive and 
negative controls in every experiment.  
Further arguments of RAGE ligands not been able to signal through canonical RAGE come 
from the fact that MLS that express the lung RAGE isoform do not respond to “RAGE” ligands 
either. Although RAGE was convincingly shown to bind “RAGE” ligands, signaling events were 
always shown to be less credible (78). RAGE signaling is thought to be of a somewhat 
inflammatory nature, so LPS contamination of the ligand could mimic RAGE signaling, as it is 
viewed at the present time. A comparison of the response of wild-type and RAGE knockout 
MLS to general pro-inflammatory stimuli (LPS, IL-1β) points to RAGE as an amplifying factor 
in the immune response as suggested (41). RAGE could interact with the pro-inflammatory 
factors released at the site of inflammation. However, it does not respond to AGEs, S100B and 
HMGB1 (Fig. 27). A more detailed study is needed to better define its role in this model as MLS 
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appear to be the only in vitro system that expressed full-length RAGE receptor at the lung 
microenvironment. 
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5.0  CHAPTER FIVE – SUMMARY AND CONCLUSIONS 
RAGE was first purified and sequenced from bovine lung extract based on its specific 
interaction with AGEs (48). It belongs to the immunoglobulin family of cell surface receptors 
and in addition to AGEs binds HMGB1, S100/calgranulin protein family members, and amyloid-
β peptides. RAGE is thought to be ubiquitously expressed with the higher levels expressed in the 
lung compared to other tissues that are thought to express “low” levels of RAGE. Ligand binding 
to RAGE is thought to trigger a whole range of cellular responses: generation of ROS and 
activation of NADPH (147), mitogen activated protein (MAP) kinase ERK 1/2 (p44/p42), stress-
activated protein (SAP) kinases p38 and JNK, and the downstream NF-κB signaling cascades 
(66, 85-87).  
Our major conclusion of Chapter 3 states that originally sequenced pulmonary RAGE 
protein, referred to herein as canonical RAGE, is only expressed in lung and thyroid. Our data 
clearly indicate that non-lung organs and cell lines express distinct non-canonical isoforms of 
RAGE. Therefore, RAGE signaling studied in non-lung organs is suspect at best. However, 
general agreement that RAGE is ubiquitously expressed supports publication every year of a 
large number of research papers regarding the role of RAGE in organs including liver, pancreas, 
and heart. Canonical RAGE is not expressed in these organs, thus it cannot play a direct role in 
the pathologies of those organs.  
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Studies of RAGE signaling in cell lines are a major concern in light of our findings. 
Studies using wild-type or RAGE-transfected cell lines are suspect for two reasons. First, in 
wild-type cells what RAGE isoform if any is responsible for signaling observed. Second, can we 
expect cell lines to express lung-specific signaling components in a non-lung environment? 
Simply transfecting cells with full-length canonical RAGE cannot be expected to upregulate 
downstream signaling components. However, the majority of RAGE studies are performed in 
cell lines! We will try to clarify these issues using several examples of animal and cell studies 
below. 
In 2005 Cataldegirmen and colleagues examined the role of RAGE in liver regeneration 
after massive liver injury (148). They observed better results in the RAGE knockout animals and 
when using anti-RAGE antibodies. Animals had better survival, better hepatocyte proliferation 
rates and more regeneration-promoting cytokines (TNFα, IL-6 and IL-10). However, the authors 
used RT-PCR and immunofluorescence in an attempt to establish RAGE expression in dendritic 
cells in the liver. Those two methods don’t detect protein size or N-glycosylation state. These 
assays can therefore lead to false positives. We know that anti-RAGE antibodies see many non-
canonical RAGE gene-derived isoforms that are present in non-lung tissues. However, their 
ligand binding and signaling have never been studied. We conclusively showed that pulmonary 
RAGE is not expressed by liver; other RAGE isoforms might be present. Interestingly, anti-
RAGE antibodies or sRAGE increased survival of the animals, suggesting some other yet 
unidentified mechanisms that are involved. Raman et al. investigated the role of RAGE in 
pathogenesis of intestinal barrier dysfunction after hemorrhagic shock and reperfusion (HS/R) 
(104). These authors never even attempted to document the expression of RAGE in this tissue. 
Regardless, sRAGE treated mice and RAGE knockouts were protected from HS/R based on 
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bacterial translocation to mesenteric lymph nodes and ileal mucosal permeability to FITC-
labeled dextran. In addition, IL-6 levels were higher and IL-10 levels were lower in the wild-type 
mice compared with the RAGE knockouts. Aleshin et al. evaluated the contribution of RAGE to 
myocardial injury (103). Although they used Western blot analysis to detect RAGE in the heart, 
the source anti-RAGE antibody was not specified, the apparent size of RAGE on the blot was not 
specified and degree of N-glycosylation was not addressed. Our data indicate that canonical 
pulmonary RAGE isoform is not expressed in the heart. However, their results also showed that 
RAGE knockout mice and mice treated with sRAGE were protected from ischemia-reperfusion 
damages. The role of RAGE was also studied in promotion of skin tumor development through 
sustained inflammation (149). These authors demonstrated that RAGE knockout mice were less 
prone to develop tumors; however, RAGE expression in the skin was shown only with 
immunofluorescense. It is common o study RAGE signaling in models that are not well defined. 
Researchers need to determine which RAGE isoform if any is responsible for RAGE signaling. 
If they use cells transformed with RAGE, then data should be confirmed in tissues expressing 
canonical RAGE (lung, thyroid).  
In spite of the problems discussed above, sRAGE can still play protective role in various 
diseases involving non-lung tissues. That is consistent with the observation of Liliensiek and 
colleagues (150) where administered sRAGE reduced inflammation in both wild-type and RAGE 
knockout animals possibly based on its interaction with potential RAGE ligands that are capable 
of triggering inflammation without RAGE. When sRAGE, which is considered to be a decoy for 
all RAGE ligands, is artificially introduced into the system, it binds them and therefore serves as 
anti-inflammatory substance. Although sRAGE seems to be protective in most studies, adding it 
to the biological system is artificial. In fact, we have never detected sRAGE in serum from 
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normal or LPS exposed rodents or human (data not shown). Up to date there is no hard evidence 
that canonical sRAGE is ever in serum. Most authors seem to show Western blots of RAGE at 
best and the degree of N-glycosylation is never addressed. It is entirely possible however, that 
some tumors, especially of lung and thyroid origin, can express canonical RAGE with correct 
degree of N-glycosylation, and consequently be able to signal correctly as is seen in type 1 
alveolocytes. This topic, though, has never been investigated. 
It is important to address usage of anti-RAGE antibodies in treatment of experimental 
diseases (reviewed in 151). For example, as it was mentioned before, Cataldegirmen et al. used 
anti-RAGE antibody in their model of regeneration after liver injury. It appeared that in their 
study, anti-RAGE treatment had a positive effect on animal survival, liver regeneration and 
cytokine expression. Our data indicate that canonical RAGE is not expressed in liver. What 
mechanisms can explain how an anti-RAGE antibody can have an effect in the tissue that does 
not express canonical RAGE and therefore does not have a pathway? We have two possibilities: 
anti-RAGE antibody binds non-canonical RAGE isoform(s) expressed in the liver and either 
blocks the signaling or signals through RAGE and induces post-induction repression. The latter 
hypothesis comes from our experiments with anti-RAGE antibody (N-16) in HMEC-1 cells 
(4.2.3). Antibody initially activated the cells making them unresponsive to IL-1β stimulation.  
This concept still needs further research which is described in the next section.   
esRAGE was first discovered by Yonekura et al. (106). They amplified cDNA from 
microvascular endothelial cells and pericytes based on the assumption that it expresses part of 
intron 9 of canonical RAGE together with the usual 8 upsteam exons. Intron 9 codes for the 
transmembrane part of RAGE protein therefore newly discovered isoform was considered 
soluble. Cheng et al. (138) performed an esRAGE profiling in human organs by 
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immunohistochemistry using the same antibody raised against esRAGE. They identified four 
types of staining with esRAGE antibody in different organs but failed to verify esRAGE protein 
size by Western blot and no N-glycosylation studies were done. Our studies indicate that 
esRAGE is of a different size and not N-glycosylated which is in disagreement with previous 
predictions made on cDNA sequence. esRAGE in mouse and human sera do not have the same 
size as canonical RAGE (our unpublished observations). In addition, anti-esRAGE antibody did 
not recognize the canonical RAGE isoform, but detected multiple bands of different sizes in 
mouse tissues (Fig. 13A). Since they were not detected in the RAGE knockout animals (Fig. 
13B), we concluded that esRAGE also comes from the RAGE gene; however it does not share 
sequences encoding the N-16 and H-300 epitope presentation. The sequence and function of 
esRAGE are still under investigation, as is the source of this protein in serum. 
In our research we established that thyroid and lung are the only tissues expressing 
canonical RAGE which correspond to 1.4 kb on Northern blot. It carries two N-glycans. We 
initially showed this in mice and have also obtained the same results in human and cow. N-
glycosylation was shown to influence RAGE ligand binding (140). All analyzed cell lines, of 
lung and non-lung origin, express 2 bands of 6 and 10 kb. RAGE isoforms from them were not 
N-glycated. When we transfected cell lines with canonical RAGE cDNA-containing plasmid, we 
can see 1.4 band on the Northern blot. However, only non-lung originated cell lines are able to 
express canonical RAGE protein with 2 N-glycans. That finding can be explained in several 
ways: mRNA stability could be affected in the lung-derived cell lines, mRNA translation could 
be compromised at the initiation and/or elongation stages. Experiments necessary to address 
these issues are proposed in the next section. 
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We believe that RAGE is only expressed in lung and thyroid and that is where we should 
study canonical RAGE signaling. There is something particular about lung microenvironment 
that allows RAGE to be transcribed and translated into the protein. Once the cells are removed 
from the lung certain roadblocks appear that prevent RAGE from being made. These findings 
can be exploited to learn more about regulation of RAGE expression in particular and lung 
development biology in general. 
We hypothesized that thyroid transcription factor 1 (TTF-1, Nkx2.1) is involved in 
RAGE mRNA production. In the early development thyroid and lung both rise from ventral 
foregut endoderm and are identified by TTF-1 by embryonic day 9. Moreover, TTF-1 is a 
necessary factor for the production of thyroglobulin (152). In addition, we were able to identify 
two TTF-1 sites on the RAGE promoter in silico. TTF-1 was shown to be expressed in the 
majority of the human lung cell lines (including A549) (153) and it could possibly affect 
canonical RAGE mRNA (1.4 kb). In addition, two other transcription factors expression, 
forkhead related activator 1 and 2 (FREAC-1 and 2), is limited to lung and placenta (137). We 
don’t exclude however other factors that could be involved in ‘canonical’ RAGE expression.  
We believe that for the reason stated above ‘canonical’ RAGE has never been studied in 
the ‘native’ lung environment. Therefore we developed an in vitro assay for RAGE signaling 
using mouse lung slices (MLS). They express RAGE and hopefully other necessary components 
for studying signaling. Initially, we used MCP-1 mRNA measured by real time RT PCR as 
readout (78). We were able to compare MLS from the wild-type mice and RAGE knockout mice 
to account for the differences in respond to the known RAGE ligands (AGEs, HMGB1 and 
S100B). Interestingly, MLS produced similar responses. We realized that when we studied 
RAGE in the only in vitro system canonical RAGE is expressed the response to the RAGE 
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ligands was absent. However, we observed differences in response to IL-1β and LPS, with the 
MLS from the RAGE knockout mice having a weaker respond. This was consistent with RAGE 
being a factor amplifying immune respond (41). We then measured a whole panel of mouse 
cytokines by a different method (Luminex™) to confirm the results. LPS-induced IL-6 and 
MCP-1 mRNA levels were different between wild-type and RAGE knockout mice at 24 h time 
point.   
In conclusion, canonical RAGE is only expressed in two tissues: lung and thyroid. Cell 
lines express a different RAGE isoform(s) that has never been characterized at the molecular 
level. MLS appear to be the only model allowing the study of canonical RAGE signaling in an in 
vitro system. Additional studies are needed to better understand the function of non-canonical 
RAGE isoforms. Ligands that bind to these proteins must be identified to allow further studies of 
signaling pathways they act on and their roles in disease processes.  
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6.0  CHAPTER SIX – FUTURE DIRECTIONS 
6.1  ‘CANONICAL’ RAGE EXPRESSION MECHANISMS 
6.1.1 Lung-derived cell lines cannot express canonical RAGE 
Lung-derived cell lines transfected with canonical RAGE are not able to produce 
canonical RAGE protein even though they express mRNA of the correct size. We propose to 
perform a series of fusion experiments with RAGE-transfected HEK293 and non-transfected 
A549 cells. HEK293 cells will express RAGE detectable by fluorescence-activated cell sorting 
(FACS). If we stably transfect each cell line with a surface marker (CD2 or CD14 for example) 
we can follow each cell type through fusion. The goal is to use FACS to sort heterokaryotic cells 
(containing more than one nucleus) that express both CD2 and CD14. These cells will have 
cytoplasm and a nucleus from both parents. If the inability of A549 cells to express RAGE 
protein is dominant then the fused cells will not express RAGE protein. In this case, we predict 
that A549 cells express some factor(s) inhibiting translation of the transfected RAGE mRNA. 
Alternatively, RAGE protein may be rapidly degraded in A549 cells. This could be due to the 
expression of RAGE-specific microRNAs, small regulatory molecules that have been shown to 
inhibit protein expression. Although the exact mechanisms of their actions are not known, they 
have been shown to work by repressing translation and/or by promoting mRNA degradation 
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(154). In this case, microRNA expressed in lung-derived cells grown outside the lung would 
prevent transcription of the ectopically expressed RAGE mRNA. Those microRNAs would not 
be expected to be expressed in the lung or thyroid tissues in situ, but would be upregulated in 
lung-derived cell lines. Several other factors are known to inhibit translation initiation and 
elongation. Eicosapentaenoic acid, for example, has been shown to inhibit translation initiation 
through a range of processes leading to inhibition of eukaryotic initiation factor 2 (155).  
If the fused cells resulting from transfected HEK293 and non-transfected A549 cells 
continue to express RAGE, it may be due to some deficiency in A549 cells that has been 
overcome by cytoplasm from HEK 293 cells. In other words, the phenotype of the A549 cells 
would be expected to be recessive. A549 cells may be deficient in transcription initiation and 
elongation factors that are lung and thyroid specific. In this case non-lung cell lines could 
express some other translation factors that are able to make up for its absence. It is also possible 
that RAGE protein is synthesized in A549 cells, but misfolded and targeted for rapid 
degradation. That could happen due to lack of correct chaperone or some other necessary factors. 
We expect that the opposite experiment (RAGE-transfected A549 cells fused with the non-
transfected HEK293 cells) would give us similar results with expression of RAGE protein being 
dependent on whether the A549 or HEK293 cell phenotypes are recessive or dominant.  
Once we know if the A549 phenotype is recessive or dominant we would proceed with 
studies to identify the factor or factors responsible for the differential expression of canonical 
RAGE protein in cell lines transfected with the RAGE cDNA. One possible approach involves 
the use of a rabbit reticulocyte lysate translation system for in vitro translation of canonical 
RAGE mRNA. To establish the system, we will first transcribe canonical RAGE mRNA in vitro 
using a plasmid containing the RAGE cDNA as a template. Then we will translate the mRNA 
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using the translation system and immunoblot to detect RAGE. After confirming this, we will add 
A549 and HEK293 cytosol to the translation system. These studies assume that the A549 cell 
phenotype is dominant. Therefore, we would expect A549 but not HEK293 cytosol to inhibit 
translation in a dose-dependent manner. Then, we will fractionate cell cytoplasm from those two 
cell lines and add different fractions from A549 cells (those that cannot make RAGE protein) 
and from HEK293 cells (those that are able to make RAGE protein) to the translation system and 
see if RAGE protein is made. Once we identify the inhibiting fraction we should work towards 
identifying the inhibiting component(s). When we identify the component(s), they should be 
verified in the translation system if they can inhibit translation when added alone.  
If the A549 cell phenotype turns out to be dominant it would imply that those cells 
express some translation inhibiting factor. A random mutagenesis strategy can be used to screen 
for this factor using RAGE protein expression as a readout. We will subject RAGE transfected 
cells to ethyl methanesulfonate, a chemical mutagen (156), and use FACS sorting to select for 
RAGE protein expressing cells. Alternatively, a panning strategy with adsorbed anti-RAGE 
antibody and washes of increasing stringency could be also used to isolate mutants that express 
RAGE (157). If, on the other hand, the HEK293 cells posses the dominant phenotype, the same 
strategy could be used, only followed by screening for mutants that would permit RAGE protein 
expression. 
One more approach for identifying factors crucial for RAGE protein expression will 
involve creating a subtraction cDNA library from A549 and HEK293 cells and HEK293 and 
A549. By doing so we would be able to identify candidate proteins that either inhibit RAGE 
protein translation or promote RAGE translation in A549 cells. This approach could be used in 
conjunction with the previous approaches, to help narrow the range of possible translation factors 
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or other genes that can be tested to reverse the mutant phenotype of cell lines created by method 
described in the previous paragraph.   
Each of these approaches has associated strengths and limitations. The use of reticulocyte 
lysate to purify factors will identify proteins functionally but we may need to use translation 
systems made from either HEK293 or A549 cells rather than rabbit reticulocytes. Another 
possible drawback is that the factor may contain two distinct factors that could be separated 
during fractionating. Such an occurance would greatly complicate this method. 
The mutagenesis approach is straight forward and isolating mutants using these strategies 
has been done for a variety of eukaryotic cells (158, 159). The difficulty is identifying the 
mutated gene. In theory this can be accomplished by introducing an expression cDNA library 
and isolating cells with a restored phenotype (160). 
The plasmid DNA can be isolated by growth in transformed bacteria. Once identified, the 
sequence of the endogenous cell line gene would be obtained to confirm the presence of a 
mutation in that gene. Finally, the substitution method will produce a set of cDNA that is 
expressed in one cell line vs. the other. These would represent candidate genes to rescue mutant 
phenotypes.  
These experiments will help us to understand the mechanisms of RAGE expression and 
hopefully lead us to elucidating the mechanisms directing organ-specific expression of lung 
specific genes. This work could have implications for other diseases where errors in pulmonary 
differentiation are involved including cystic fibrosis and chronic pulmonary fibrosis.    
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6.1.2 Identifying RAGE isoform mRNA via Northern blot and cDNA library 
screening 
In Section 3.2.2 we discussed RAGE and RAGE-related mRNA transcripts in various 
tissues and cell lines. These studies could be substantially improved by using RAGE knockout 
mice as negative controls for mouse organs. We were able to identify pulmonary RAGE 
isoforms in thyroid, so thyroid tissues should be added to the Northern blot panel. We used 
human probe to analyze RAGE mRNA from mouse tissues. Ideally, these studies should be 
repeated using a mouse cRNA probe. We expect thyroid to express the same mRNA transcript as 
lung and transfected cell lines (1.4 kb). It would be informative to use a probe that corresponds 
to the amino acids encoding the epitopes recognized by N-16 anti-RAGE antibody. This would 
presumably allow detection of messages for non-canonical RAGE isoforms that were observed 
using Western blot. The same experiments should be performed with a cRNA probe spanning the 
esRAGE intron 9 sequence to identify authentic esRAGE mRNA species. Studies performed by 
others (45, 106) in order to detect RAGE isoforms, utilized primers known to amplify canonical 
RAGE. We showed that N-16 and H-300 do not recognize esRAGE on the Western blot, 
therefore those exons cannot be not included in esRAGE sequence.  Hudson et al. (45) cloned 
and sequenced RAGE isoforms based on the assumption that they included some exons from 
canonical RAGE. Both groups used a PCR amplification step with RAGE primers and later 
expressed newly discovered cDNAs in the HEK293 (45) and COS-7 (106) cell lines, permissive 
for expressing canonical RAGE. Lung cell lines do not express canonical RAGE protein in spite 
of expressing RAGE cDNA, so it is unclear if real tissues would inhibit expression of the other 
RAGE isoforms. 
 79 
Instead, we propose to create a lung cDNA library with any commercially available kit 
(The SuperScript® Plasmid System, Invitrogen, CA, for example). We will take mRNA and 
reverse transcribe it with high efficiency RT transcriptase (SuperScript™ II RT for the 
Invitrogen kit). That would result in complete cDNA sequences that could be screen with N-16 
and esRAGE sequences for the possible RAGE isoform candidates.  This way we will not limit 
screening to the mRNA sequences located within canonical RAGE sequence and avoid errors 
introduced by the PCR amplification step. 
Another way to identify protein RAGE isoforms will be to fluorescently label anti-RAGE 
antibody (or Fab fragments, described in details in section 1.2.1), bind them to the cell line and 
crosslink the antibody, isolate proteins from plasma membrane and run them on a 2-D gel. We 
will then visualize fluorescent spots, isolate them then sequence them by mass spectrometry 
analysis.  This has the potential to identify RAGE gene encoded proteins expressed in cell lines. 
6.1.3 Utilizing primary type 1 alveolar cell lines from wild-type and RAGE 
knockout mice to characterize cell line RAGE 
We were not able to find a single cell line expressing canonical RAGE. Given that most 
RAGE signal transduction studies are performed in cell lines that do not express canonical 
RAGE protein, it seems appropriate to confirm that the bands recognized by N-16 and ES are 
shown to be generated from the RAGE gene. This can be done by growing primary cell lines 
(161) from different tissues obtained from both wild-type mice and RAGE knockout mice and 
comparing their RAGE protein expression. We will choose tissues representing different organs, 
including lung, liver, and intestine with and without transfection with large T antigen to 
immortalize the cells. We will use cell-specific marker to differentiate specific cell types. 
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Markers of mature hepatocytes, for instance, include albumin, glucose-6-phosphatase, tyrosine 
aminotransferase, cytochrome P450-3a, phosphoenolpyruvate carboxykinase and tryptophan 2,3-
dioxygenase (162). Caveolin-1 and 2, T1α, ICAM-1, connexin-43 could serve as markers for the 
type 1 alveolocytes (163). We expect to lose the expression of canonical RAGE in the cultures 
from wild-type mice. We also expect to lose all RAGE isoforms in the cell lines derived from the 
knockout animals. Cells derived from wild-type mice will probably lose their RAGE expression, 
but will likely express a cell line specific RAGE isoform. Cells grown from the RAGE 
knockouts will not have canonical RAGE and will not have cell line RAGE. By comparing two 
cell lines of the same tissue type from wild-type and knockout mice pair-wise on Western blot 
we will distinguish cell line mouse RAGE isoform(s) and will hopefully be able to obtain 
primary protein from them and sequence it. This set of experiments will help the field and speed 
future RAGE research. 
   
6.1.4 Lung and thyroid specific transcription factors could drive canonical RAGE 
mRNA expression  
While RAGE role and significance are studied extensively in different tissues, little is 
known about tissue-specific RAGE expression and the factors driving it. The question still 
remains: why lung-derived cell lines (A549 and CaLu-3) are not expressing RAGE mRNA while 
the lung tissue is the major RAGE-expressing tissue in the body. We propose to investigate lung 
and thyroid specific transcription factors and determine if they play role in canonical RAGE 
mRNA transcription. 
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Thyroid transcription factor 1 (TTF-1) has been shown to be expressed in lung and 
thyroid as early as 9 days of embryonic development in mice (141). We speculate that TTF-1 
could induce canonical RAGE mRNA or protein expression in vitro. In silico studies of the 
mouse RAGE promoter confirmed the existence of two TTF-1 binding sites. In addition, TTF-1 
is utilized in clinical applications for separating metastatic carcinoma from primary lung cancer 
(164). Therefore, we plan to transfect TTF-1 and see the effects on RAGE transcription. We 
know that when we transfect canonical RAGE cDNA into lung-derived cell lines they do not 
make RAGE protein. Thus, we will co-transfect RAGE and TTF-1 into the lung-derived cell line 
(A549) and look for RAGE expression. TTF-1 was shown not to be expressed in A549 cells; 
however other lung cancer cell lines express the protein (153). We are planning to screen other 
lung cancer cell lines for both RAGE and TTF-1 expression. We could also correlate TTF-1 and 
RAGE expression in lung and thyroid cell lines.  
It is also possible that RAGE expression in the lung is driven by other transcription 
factors involved in lung morphogenesis. Other than TTF-1, this group includes β-catenin, 
Forkhead orthologs (FOX), GATA, SOX and ETS family members (165). Two approaches are 
possible. First, we can obtain expression plasmids of these factors, transfect them into A549 or 
any other lung-derived cell line together with the canonical RAGE plasmid and look for the 
canonical RAGE protein expression by Western blot. Second, we could assay those transcription 
factors in several available to us lung-derived cell lines, comparing it to the expression pattern of 
RAGE-expressing tissues (lung and thyroid).  This way we could determine which factor(s) is 
permissive to express canonical RAGE. 
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6.1.5 Determine X-RAGE sequence 
We identified a slightly bigger novel lung RAGE isoform which was initially induced in 
mice by LPS at 1 h in vivo and continued to be expressed for at least 48 h.  We know that LPS-
treated mice did not have an additional transcript on the Northern blot (unpublished 
observations), therefore x-RAGE should come from the same canonical RAGE transcript. We 
were able to confirm that it shares some similarities with the ‘canonical’ mouse RAGE with 
mass spectrometry sequence analysis but did not determine the exact difference. We are planning 
on continuing this work. First, we are going to repeat the procedure that we did initially, which 
include injecting mice with 2 mg/ml LPS and harvesting lungs in 24 h. We are going to purify x-
RAGE and use methods described in Chapter 3 to sequence it.  We would need to extend 
sequence coverage in comparison with the experiment we did before.  
If it does not work we are planning to do an immunoaffinity caption of the mouse lung 
lysate with N-16 anti-RAGE antibody, fractionate the purified product on the 2D gel and 
perform Adman degradation coupled with mass spectroscopy. x-RAGE could play a role in the 
inflammatory response to LPS, or it could still contain pro-peptide in the sequence. Once the 
modification is established, its significance could be studies further.  
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6.2 RAGE SIGNALING 
6.2.1 RAGE ligand signaling in cell lines 
Exposing HMEC-1 cells to the RAGE ligands HMGB1 and S100B decreased and 
increased MCP-1 steady-state mRNA levels, respectively (135). S100B induced MCP-1 
production was blocked by applying an anti-RAGE antibody (N-16). The same antibody was 
used in a paper previously published by our laboratory showing that it also blocked HMGB1-
induced hyperpermability in CaCo-2 cells (145). This particular antibody (N-16) was also used 
by other researchers with the similar effects: Ding et al. blocked O2– generation by mononuclear 
phagocytes in diabetes (166) and Bianchi et al. diminished pro-inflammatory effects of S100B in 
microglial cell line (167). Other antibodies against the N-terminus of RAGE were also 
successfully used to block RAGE signaling. In our previous studies we were not able to detect 
canonical RAGE protein in HMEC-1 cells. These cells appeared to express a different RAGE 
isoform (168). In our hands, HMGB1, a RAGE ligand, did not increase NF-B activation and 
this is important for increased iNOS expression and permeability. We wondered if anti-RAGE 
antibody was acting through another mechanism than blocking ligand binding to non-canonical 
RAGE. 
When we blocked S100B and HMGB1 signaling in HMEC-1 cells with anti-RAGE 
antibody we also blocked responses to IL-1β, which was used as a positive control for MCP1 
induction. The question becomes whether N-16 works through RAGE or does it interfere with 
some signaling events that are shared between RAGE and IL-1β signaling cascades.  To test this 
possibility we performed a time course with HMEC-1 cells and N-16 antibody, using MCP1 as a 
readout. It turned out that N-16 anti-RAGE antibody stimulates MCP1 production in HMEC-1 
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cells as early as 2 h and the response was down-regulated by 24 h. We hypothesize that N-16 
antibody could dimerize the non-canonical RAGE expressed in all cell lines and activate it that 
way. That impacts responses to other stimuli (like IL-1β) through post-inductional repression.  
To test this hypothesis we will use Fab fragments of N-16 antibody. We will digest the 
antibody with papain, a thiol-endopeptidase, to cleave whole IgG just above the hinge region and 
to create two separate Fab fragments and one Fc fragment per antibody molecule (kit from 
Pierce, IL).  This way when the Fab fragment binds to RAGE it will not dimerize it. We 
hypothesize that if we use fragments instead of the whole antibody it will not activate HMEC-1 
cells. The correct control will be performed by dimerizing Fab fragments back after they bind the 
receptor. Anti-goat Fab antibody could be used for this purpose. This will result in cross-linking 
of non-canonical RAGE which would induce a signal and post-induction repression as predicted.  
To confirm that the same thing was happening in other publications including our own 
(145, 166, 167) we will first use N-16 anti-RAGE antibody in their models and try to block 
RAGE-dependent responses. If it works we’ll try to perform experiments with the Fab fragments 
with and without cross linking. These experiments will be important for understanding the role 
of non-canonical RAGE and what steps should be taken to study RAGE signal transduction. It is 
also important to understand that N-16 blocking antibody does not work through canonical 
RAGE.  
6.2.2 Canonical RAGE signaling in MLS 
We established that canonical RAGE is only expressed in lung and thyroid.  We also 
showed that none of our tested cell lines expressed canonical RAGE. Although non-lung cell 
lines are able to expressed canonical RAGE protein when transfected, they might not express 
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lung-specific factors that could be necessary for RAGE signal transduction (Chapter 3 and 168). 
MLS was the only tested in vitro system that permitted canonical RAGE expression in culture. 
We tested canonical RAGE expression for up to a week after harvest and levels of expression did 
not change.   
We are planning on using MLS to study canonical RAGE ligands and signaling by 
comparing responses of wild-type and RAGE knockout mice. Preliminary studies showed that 
MLS from those mice do not respond differently to the known RAGE ligands (AGEs, S100B and 
HMGB1) but they exhibit weaker responses to IL-1β and LPS (4.2.5 and 4.2.6). These findings 
suggest that RAGE might play a role in the amplifying of inflammatory response through 
secondary signaling components. Therefore we acquired mRNA samples from wild-type and 
RAGE knockout mice during 24 h time course. Conditions included responses to IL-1β and LPS, 
with and without anti-RAGE blocking antibody (N-16). We hypothesize that N-16 will activate 
MLS from the wild-type mice impairing their respond to IL-1β and LPS. RAGE knockout mice 
would not likely be effected by N-16 anti-RAGE antibody. When all the data is processed we 
can build a model for activation of different genes with and without RAGE.  
We are also planning on performing a gene array in the MLS from wild-type and RAGE 
knockout mice at an early time point (2 h) and find new gene candidates for RAGE signaling. 
Then we are going to determine their role in inflammation.  These genes could be new targets in 
the diseases that involve RAGE. 
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7.0  CHAPTER SEVEN - MATERIALS AND METHODS 
7.1 REAGENTS 
All reagents were purchased from Sigma unless stated otherwise. S100B expression plasmid 
provided by Dr. Gary S. Shaw (University of Western Ontario, Canada) was expressed in E. coli 
N99/pSS2 and purified as described (169).  S100B tested negative for LPS. 
7.2 CELL LINES 
Human THP-1 (American Type Culture Collection #TIB-202) myeloid cells were maintained in 
RPMI 1640 supplemented with 10%  FBS, 1mM of sodium pyruvate, and 1% penicillin-
streptomycin. HMEC-1 cells, a human microvascular endothelial cell line immortalized with 
SV40 large T antigen, were provided by Dr. Edwin Ades (National Center for Infectious 
Diseases, Atlanta, Georgia, USA) (144).  They were routinely maintained in MCDB 131 medium 
(Invitrogen Corporation, Carlsbad, CA) supplemented with 10% FBS, 10 ng/ml EGF, 1 μg/ml 
hydrocortisone, 10 mM L-glutamine, 1% penicillin-streptomycin.  Caco-2 human enterocyte-like 
cells (ATCC #HTB-37) were cultured as described (145). Human A549 lung epithelial cell line 
was purchased from ATCC (ATCC #CCL-185) and maintained in F-12 Kaighn’s medium 
(Invitrogen) supplemented with 10% FBS, 2 mM L-glutamine and 1% penicillin-streptomycin.   
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Human HEK 293 embryonic kidney cell line was purchased from ATCC (ATCC #CRL-1573) 
and maintained in minimal essential medium (Eagle) with 10% FBS, 0.1 mM non-essential 
amino acids, 1 mM sodium pyruvate and 1% penicillin-streptomycin. Rat type 1 alveolocytes 
(R3/1) were provided by Dr. Ronald Koslowski of Dresden University of Technology (Dresden, 
Germany) and maintained as described (163). Mouse cell lines CMT-93 (polypoid carcinoma, 
ATCC #CCL-223), LA-4 (lung adenoma, ATCC #CCL-196), MES-13 (mesangial cells, ATCC 
#CRL-1927), NIH 3T3 (fibroblasts, ATCC #CRL-1658), RAW 264.7 (macrophages, ATCC 
#TIB-71) and Y-1 (adrenal cortex, ATCC #CCL-79) were maintained exactly as described by 
ATCC. Mouse lung fibroblasts were created by immortalization as described (170).  
All cell lines were passed once a week and grown at 37 °C in a humidified incubator 
maintained with 5% CO2 and 95% air. C57BL/6 mice were obtained from the Jackson 
Laboratory (Bar Harbor, Maine).  All cell culture lines were routinely tested on a monthly basis 
for Mycoplasma contamination using the Lonza MycoAlert® Mycoplasma Detection Kit 
(Rockland, ME).  
RAW 264.7 mouse macrophage-like cells were plated in 6-well plates and were used the 
following day. They were stimulated by adding 100 ng/ml Escherichia coli LPS (serotype 
O111:B4) in the presence or absence of graded concentrations of the tested compounds. Nitrite 
and IL-6 concentrations were measured in 18 h in cell supernatants using commercially available 
Griess reaction kit (Oxis International, Portland, OR) and commercially available R&D Systems 
Quantikine Immunoassay Kit for IL-6. Cells were used for the real time reverse transcriptase 
PCR analysis. 
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7.3 CELL-BASED ASSAY FOR STUDYING THE RELATIVE PHARMACOLOGY 
OF THE ANTI-INFLAMMATORY DRUGS 
Human astrocytoma cell line (U-373) expresses virtually no intracellular adhesion molecule-1 
(ICAM-1, CD54) without pro-inflammatory stimulation (30). When stimulated with the pro-
inflammatory stimuli (IL-1β) 50-60% of the cells start expressing ICAM-1 (CD54). We decided 
to use this cell line for the cell-based pharmacological assessment of the potential anti-
inflammatory drugs because of the simplicity of the assay (fluorescence activated cell sorting 
(FACS)). This way we were able to utilize endogenous reporter gene instead of the transfected 
one. First, we stimulated the cells with IL-1β and used FACS to enrich the cell population for 
CD54-positive cells. Resulting bulk cell population was found to express CD54 in a higher 
percentage of cells (70-98%) compared to the parental population. We used the bulk cells as well 
as clonal cell lines (1-6). Clonal cell lines expressed different degrees of being CD-54-positive. 
To confirm that ICAM-1 was indeed NF-κB-dependent gene we used a protease inhibitor N-
tosyl-L-phenylalanine chloromethyl ketone (TPCK) to block proteasome activity and this almost 
completely blocked upregulation of CD54 expression on these cells. The percent of the CD-54 
positive cells increased with the IL-1β concentration used – dose-response curve (Fig. 7). We 
have used this endogenous NF-κB reporter system to study the relative efficacy of several 
compounds that have similar chemical properties to ethyl pyruvate, a promising new candidate 
compound for treatment of a variety of systemic and localized inflammatory diseases. 
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7.4 TESTED COMPOUNDS 
Tested compounds included ethyl pyruvate (EP), sodium pyruvate (SP), benzoyl formic acid 
(BF), and p-hydroxyphenylpyruvic acid (pHPP).They were purchased from Sigma-Aldrich 
Chemical Co. and there molecular structures are presented in Fig. 29. 
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7.5 FLOW CYTOMETRY ANALYSIS 
U373 astrocytoma clonal cells were cultured in the 6-well plates as described above in the 
presence or absence of IL-1β (10 ng/ml) and in either the absence or presence of one of the test 
compounds. Cells were harvested with 10 mM EDTA in PBS, washed with DMEM and then 
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Figure 29. Molecular structure of the enone forming compounds (A,B,C) and one
compound that does not isomerize to an enone (D).  
Various isomers are shown for some molecules. The enone moiety is shown in red.
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incubated either with a FITC-conjugated anti-human CD54 monoclonal antibody or a FITC-
conjugated mouse IgG2a isotype control antibody (CALTAG lab., Burlingame, CA). Cells were 
fixed with 2% paraformaldehyde in PBS and analyzed by flow cytometry.  
 
7.6 PHARMACOLOGIC ANALYSIS USING FACS ANALYSIS 
Percent inhibition for each compound was determined by comparing mean channel 
fluorescence (MCF) of the cells stimulated with IL-1β with the MCF of the cells which were 
pretreated with the drug of interest prior to treatment with IL-1β, according to the formula: % 
inhibition = (MCF of the sample - MCF of unstimulated cells 1)/(MCF of IL-1β-treated cells – 
MCF of unstimulated cells). 
7.7 PROTEIN N-GLYCAN REMOVAL 
 Peptide: N-Glycosidase (PNGase) F (New England BioLabs) was used to remove N-linked 
glycans from protein according to the manufacturer’s instructions. Briefly, we denatured equal 
amounts of protein (50 μg) in Glycogen Denaturing Buffer, containing 5% SDS and 0.4 M DTT 
by heating at 100 °C for 10 m. After cooling the mixture the reaction buffer G7 (0.5 M sodium 
phosphate, pH 7.5) and 10% NP-40 were added at 1/10 volume each. 500 units of PNGase F 
were added and samples were incubated for 3 h at 37 °C. Control reactions contained the same 
buffer without enzyme. Proteins were analyzed using Western blot.   
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7.8 WESTERN BLOTTING 
 Equal amounts of total protein extract mixed in 1 × Laemmli buffer were boiled for 5 min and 
centrifuged for 10 s. The supernatants were electrophoresed on reducing 8% or 10% SDS-
polyacrylamide gels.  The proteins were electroblotted onto Hybond-P polyvinylidene difluoride 
membranes (GE Healthcare, Piscataway, NJ) and blocked with Blotto (1 × Tris-buffered saline, 
5% non-fat dry milk, 0.05% Tween-20, and 0.2% NaN3) for 60 min.  The filters were incubated 
at 4 ºC overnight with primary anti-RAGE antibody (H-300 and N-16; (Santa Cruz Biotech, 
Santa Cruz, CA) or anti-esRAGE (Dr. Takuo Watanabe and Dr. Hiroshi Yamamoto) in fresh 
blocking buffer, washed 3 times in PBST and incubated with the appropriate secondary antibody.  
After three washes in PBST the membrane was impregnated with enhanced chemiluminescence 
substrate (GE Healthcare) and used to expose X-ray film (Blue Ultra Autorad Film, ISC 
BioExpress, Kaysville, UT).  
We routinely run 20 μg of protein per lane for extracts prepared from cell lines, but only 
use 5 μg of mouse lung protein extract per lane to detect RAGE by Western. However, it was 
necessary to decrease the concentration of dry milk in the blotting solutions (1.5% vs. 5% final 
concentration) in order to reproducibly obtain a strong signal on Western analysis when probing 
cell line extracts.  The N-16 antiserum was raised in goats using a peptide representing the 
amino-terminus of human pulmonary membrane RAGE.  Anti-RAGE antibodies tested for 
recognition of RAGE isoform expression in cell lines included a rabbit polyclonal antibody 
generated against a fragment of the human pulmonary membrane RAGE isoform including 
amino acids 1-300 (H-300). Both antibodies were obtained from Santa Cruz Biotech (Santa 
Cruz, CA).  Monoclonal anti-esRAGE antibody was provided by Dr. Takuo Watanabe and Dr. 
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Hiroshi Yamamoto of Kanazawa University Graduate School of Medical Science (Kanazawa, 
Japan). 
7.9 ANIMAL AND HUMAN TISSUES 
 Human tissues were obtained postmortem from UPMC Presbyterian Hospital. The 
research described in this paper involving the use of human beings adheres to the principles of 
the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of 
Human Subjects, Revised November 13, 2001, effective December 13, 2001.   
All study protocols using rats and mice followed the guidelines for the use of 
experimental animals of the U.S. National Institutes of Health and were approved by the 
Institutional Animal Care and Use Committee at the University of Pittsburgh.  Male Sprague-
Dawley rats (Charles River Laboratories, Wilmington, MA), weighing 150 to 250 g, and male 
C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) weighing 20–25 g were housed in a 
temperature-controlled environment with a 12-h light/dark cycle with free access to standard 
laboratory chow and water.  Animals were not fasted prior to the experiments. To induce a 
systemic inflammatory response, mice were injected intraperitoneally with E. coli (strain 
0111:B4) LPS, 2 mg/kg dissolved in 0.2 ml of phosphate-buffered saline (PBS). Control animals 
were injected with the same volume of PBS.  Tissues were harvested from animals at the times 
indicated in the text following intraperitoneal injection with sodium pentobarbital (35 mg/kg). 
Tissues from RAGE knockout animals were obtained from the laboratory of Dr. Tim Oury at the 
University of Pittsburgh (32). 
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7.10 MOUSE LUNG SLICES 
Mice were sacrificed by intraperitoneal injection with sodium pentobarbital (35 mg/kg). Lungs 
were perfused through the heart with the PBS. Lungs were removed using aseptic techniques and 
places into PBS solution on ice. McIlwain tissue chopper (Mickle Laboratory Engineering Co. 
Ltd., United Kingdom) was used to cut the lungs transversely. The slice thickness was chosen to 
be 0.7 mm which is predicted by Warburg equation: C1=C0-A/D*d2/8, where C1 is the pO2 in the 
deepest layer of the slice; C0 is the pO2 at the surface of the slice; A is oxygen uptake of the slice 
in ml/min/ml of tissue; D – diffusion coefficient in ml of oxygen/cm2/min; d – slice thickness in 
cm (171, 172). After being cut the slices were placed into the 10 mm dish filled with PBS and 
washed with agitation. Then 6 pieces were placed into each well of the 6-well plate. The slices 
were maintained in the RPMI-1640/Ham’s- F12 medium (Lonza Group Ltd., Switzerland) (1:1) 
supplemented with 10% FBS and 1% penicillin-streptomycin. The tested reagents were applied 
in 1 h after seeding. The slices were harvested in TRI-Reagent as directed by the manufacturer 
(Molecular Research Center, Cincinnati, OH) at the time indicated and used for real time PCR. 
All experiments were performed in triplicate.   
7.11 PRIMARY LUNG CELL CULTURE 
Mouse lungs we extracted using aseptic techniques and placed in cold PBS on ice.  They were 
cut into pieces with the sterile scalpel in a sterile tissue culture hood and placed in medium 
containing 1.0 mg/ml protease 14 (Sigma P-5147) plus 10 μg/ml DNase I (Sigma DN-25) in 
HAMs F12 medium (Invitrogen).  The lung pieces were incubated overnight with gentle 
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agitation.  The next morning the cells were spun down at approximately 800 ×g for 5 min and 
washed 4 times in RPMI-1640/Ham’s-F12 (1:1) supplemented with 15% FBS, 10 mM L-
glutamine, 1% penicillin-streptomycin.  The cells were plated on collagen coated plates (Biocoat 
Plastics, Becton Dickinson, Framingham, MA) in the same medium.  The medium was changed 
the next day to remove the dead cells. 
7.12 NORTHERN BLOT ANALYSIS 
Total RNA was isolated from cells and tissues using TRI-Reagent as directed by the 
manufacturer (Molecular Research Center, Cincinnati, OH).  For Northern blot hybridization 2-
10 μg of total RNA from each sample was separated on a 1% denaturing agarose gel containing 
1% formaldehyde.  RNA was transferred onto Hybond–N+ positive nylon membrane (GE 
Healthcare) overnight by capillary blot.  The membrane was prehybridized for 30 min-1 h at 68 
ºC using Ultrahyb (Ambion, Austin, TX).  Full-length human RAGE cDNA (GenBank 
Accession #NM_001136) served as a template to synthesize a complementary RNA probe for 
hybridization using [32P]-UTP. The membrane was washed using the standard stringency 
conditions recommended by the manufacturer (Ambion) then used to expose X-ray film at -80 ºC 
using an intensifying screen. 
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7.13 PURIFICATION AND MASS SPECTRAL ANALYSIS OF MOUSE LUNG RAGE 
ISOFORMS 
 Lungs were prepared from 10 mice 18 h after injection with 2 mg/ml of LPS.  Total protein was 
isolated using RIPA buffer supplemented with 1% CHAPS, which increased RAGE protein yield 
when tested using Western blot.  RAGE was captured on a 19.5 ml DEAE Sepharose CL4B 
column equilibrated with Buffer A (20 mM Tris, pH 7.5, 50 mM NaCl, 1% CHAPS, and 1 mM 
DTT).  The column was washed with 1.5 column volumes (CV) of buffer A then eluted using 1.5 
CV with 18% Buffer B (Buffer A with NaCl increased to 1 M), 1.5 CV of 43% Buffer B, 
followed by 100% Buffer B.  RAGE was detected in different fractions was using Western 
blotting.  Fractions from step two were enriched for pulmonary membrane and X-RAGE 
isoforms.  Fractions were pooled and applied to a 10 ml column of concanavalin A Sepharose at 
0.5 ml per h at 4 ºC.  The first flow through was collected and reapplied to the column before 
washing to baseline absorbance using 4 CV of Buffer A containing 250 mM NaCl.  Proteins 
were eluted using wash buffer containing 0.5 M αD-methyl mannopyranoside.  Buffer was 
exchanged to 20 mM Tris, pH 8.0, 50 mM NaCl, 0.2% CHAPS, and 1 mM DTT using a 50 ml 
G25 column.  Proteins were captured and concentrated using a 1 ml Mono Q anion exchange 
column equilibrated with the same buffer.  The column was developed using a linear gradient of 
20 CV ending with 1 M NaCl in the start buffer.  Fractions containing RAGE were pooled and 
concentrated using ultrafiltration.  Samples were resolved on an 8% reducing SDS-PAGE gel 
which was stained with Coomassie to visualize the bands for excision with a glass micropipette.  
The gel plugs were digested with trypsin overnight at 37 ºC.  Eluted peptides were analyzed 
using a Applied Biosystems MALDI-TOF MS/MS running in reflection mode.  The collection 
window was set to 799 to 4013 m/z.  The mass spectrum was analyzed using Data Explorer 
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(Applied Biosystems), and calculated peptide mass to charge ratio was calculated and used to 
identify peptides using Aldente (173) (http://www.expasy.org/tools/aldente/). 
7.14 REAL-TIME REVERSE TRANSCRIPTASE-PCR ANALYSIS 
 Cells were plated in 6-well plates and exposed to various treatments the following day.  Cells 
were harvested in 1 ml of TRI-Reagent as directed by the manufacturer (Molecular Research 
Center, Cincinnati, OH).  Bromochloropropane was used for the extraction.  The final RNA 
pellet was dissolved in nuclease - free water and quantified using a GeneQuant pro UV 
spectrophotometer (GE Healthcare).  Extracted RNA (1 μg /reaction) was converted to single-
stranded cDNA in a 20 μl reaction using the Reverse Transcriptase System Kit (Promega) as 
directed by the manufacturer.  The mixture was heated to 70 ºC for 10 min, maintained at 42 ºC 
for 30 min, and then heated to 95 ºC for 5 min using a Gene Amp PCR System 9700 (Applied 
Biosystems, Foster City, CA).  TaqMan Gene Expression Assays for MCP-1, iNOS and 18S 
RNA (endogenous control) and real-time PCR reagents were from Applied Biosystems (Foster 
City, CA). Reaction mixtures for PCR were assembled as follows:  10 μl TaqMan Universal 
PCR Master Mix, 1 μl of each Gene Expression Assay mix, 1 μl cDNA template and 7 μl of 
water.  PCR reactions were performed in an Applied Biosystems thermocycler 7300 Real Time 
PCR System by incubating at 50 ºC for 2 min, 95 ºC for 10 min, 95 °C for 15 s, and 60 ºC for 1 
min; the two final steps were repeated for 40 cycles.  Each sample was assayed in duplicate and 
the values were averaged.  A ΔΔ Ct relative quantification method was used to calculate mRNA 
levels for MCP-1 in the samples.  Results were first normalized relative to 18S rRNA expression 
levels and then to the control (calibrator).   
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7.15 ANALYSIS OF MOUSE CYTOKINE MRNAS  
Mouse lung slices were prepared and treated as described in 5.10. mRNA from mouse 
lung slices was extracted as described in 5.14. Mouse cytokines were detected using a 
LuminexTM 100 IS apparatus using the BioSource International Mouse 20-plexs LuminexTM 
beadset. QuantiGene Plex 2.0 assays combine branched DNA (bDNA) signal amplification 
technology and xMAP® (multi-analyte profiling) beads to enable simultaneous quantification of 
multiple RNA targets directly from cultured cell or whole blood lysates; fresh, frozen or 
formalin-fixed, paraffin-embedded (FFPE) tissue homogenates; or purified RNA preparations. 
Branched DNA technology is a sandwich nucleic acid hybridization assay that provides a unique 
approach for RNA detection and quantification by amplifying the reporter signal rather than the 
sequence. By measuring the RNA at the sample source, the assay avoids variations or errors 
inherent to extraction and amplification of target sequences. The xMAP system, developed by 
Luminex Corp, combines flow cytometry, fluorescent-dyed microspheres (beads), lasers and 
digital signal processing to effectively allow multiplexing of up to 100 unique assays within a 
single sample. 
 
7.16 ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA) 
The EMSA used to measure DNA-binding activity was carried out using a double 
stranded oligonucleotide (174). Briefly, the sequence of the double-stranded NF-κB 
oligonucleotide was as follows: sense, 5'-AGT TGA GGG GAC TTT CCC AGG C-3'; antisense, 
 99 
3'-TCA ACT CCC CTG AAA GGG TCC G-5' (NF-κB DNA binding consensus sequence is 
underlined; Promega). The oligonucleotides were end-labeled with γ-[32P]-ATP (PerkinElmer 
Life and Analytical Sciences, Boston, MA) using T4 polynucleotide kinase (Promega). Three 
micrograms of nuclear protein/reaction or 10 µg of total cellular protein was incubated with 
radiolabeled NF-κB probe in band shift buffer (10 mM Tris, pH 7.8, 40 mM KCl, and 1 mM 
EDTA) in the presence of 2 µg of poly(dI·dC) for 20 min at room temperature. The binding 
reaction mixture was electrophoresed on 4% nondenaturing polyacrylamide gels, which were 
then dried and used to expose Kodak X-omat AR film (Eastman Kodak, Rochester, NY) at 80°C 
overnight using an intensifying screen.  
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APPENDIX A 
ABBREVIATIONS 
ET – ethyl pyruvate  
SP – sodium pyruvate  
pHPP – para-hydroxyphenyl pyruvate 
BF – benzoyl formate 
AGE – advanced glycation end-products 
HMGB1 – high mobility group box-1 
S100B – S100 calcium binding protein B 
IL1-β – interleukin 1 β 
NF-κB – nuclear factor-kappa B 
RAGE – receptor for advanced glycation end-products 
sRAGE – soluble RAGE 
CD54 – cluster of differentiation 54, the same as ICAM-1 
ICAM-1 – inter-cellular adhesion molecule 1 
MCP-1 – monocyte chemoattractant protein 1 
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PUBLICATIONS 
B.1 PAPERS 
Aneja RK, Tsung A, Sjodin H, Gefter JV, Delude RL, Billiar TR, Fink MP (2008) 
Preconditioning with high mobility group box 1 (HMGB1) induces lipopolysaccharide 
(LPS) tolerance. J Leukoc Biol 84:1326-1334 
Gefter JV, Shaufl AL, Fink MP, Delude RL (2009) Comparison of distinct protein isoforms of 
the receptor for advanced glycation end-products expressed in murine tissues and cell 
lines. Cell Tiss Res, in press.  
Gefter JV, Cotoia A, Englert JA, Delude RL. Treatment with p-hydroxyphenylpyruvate without 
resuscitation extends survival in a rat profound hemorrhagic shock model. (in 
preparation) 
Macias CA, Killeen ME, Arora DS, Gefter JV, Sarumi O, Fink MP, Wipf P, and Delude RL. 
Nitroxyl-gramicidins block MAP kinase activation, NO·, HMGB1, and IL-10 release. (in 
preparation) 
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Macias CA, Liachenko JV, Delude RL, Fink MP (2005) Primary rat hepatocytes tolerate 
prolonged periods of   oxygen/glucose deprivation (OGD) without losing viability. 
Lippincott Williams & Wilkins, pp A35-A35 
Gefter JV, Shaufl AL, Fink MP, Delude RL (2006) Molecular analysis of receptor for advanced 
glycation end-products isoforms expressed in tissues and cell lines. Lippincott Williams 
& Wilkins, pp A29-A29 
Gefter JV, Fink MP, Delude RL (2008a) Lung-specific isoforms of Receptor for Advanced 
Glycation End products (RAGE) are distinct from those expressed in other tissues and in 
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